UF-STO-ETI-001  14 February 2022 
1 of 92  
       CONFIDENTIAL   Version 2. 2  A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and other DNA Damage 
Response (DDR) Pathway Deficient Neoplasm s 
 
Protocol Number:    UF-STO-ETI-001 
UF IRB # :    201701827  
Coordinating Center:    University of Florida  
Principal Investigator:   Thomas George, MD, FACP  
University of Florida  
1600 SW Archer Road  
Gainesville, FL 32608  
Telephone: (3 52) 265 -0725  
Fax: (352) 265 -0735  
Email: Thom.George@medicine.ufl.edu  
 
Translational Co -Investigator:  Robert Hromas, MD, FACP  
University of Texas Health San Antonio  
Phone: (210) 567 -4432  
Email: hromas@uthscsa.edu  
 
Junior Principal Investigator:   Aaron Franke, MD, MS  
     University of Florida  
     Telephone: (352) 273 -9167  
     Email: Aaron.Franke@medicine.ufl.edu  
 
Statistician:     Ji-Hyun Lee , DrPH  
University of Florida Health Cancer Center  
   Telephone:  (352) -273-9079  
   Email: jihyun.lee@ufl.edu  
 
Protocol Manager (s):   UFHCC Project Management Office  
pmo@cancer.ufl.edu   
 
 
 
 
 
UF-STO-ETI-001  14 February 2022 
2 of 92  
       CONFIDENTIAL   Version 2. 2  CONFIDENTIAL  
This protocol was designed and developed by the University of Florida Health Cancer Center. The information contained in this  document is regarded as confidential and, except to the extent 
necessary to obtain informed consent, may not be disclosed to another party unless law or regulations require such disclosure. Persons to whom th e information is disclosed must be informed that 
the information is confidential and may not be further disclosed by them.  
 
 
 
 Clinical Phase:     Phase II  
IND Status:     IND 138517 ( Exempt ) 
NCT# :     [STUDY_ID_REMOVED]  
Investigational Agent(s):   Niraparib (TESARO /GSK , Inc.)  
Date of Original Protocol:   January 31, 2017  
Date of Current Protocol:   February 14, 2022  
Version of Current Protocol:         2.2 
PROTOCOL REVISION  RECORD       Version 1.2, dated 04 -SEP-2018  
                                                             Version 1.3, dated 13 -MAR -2019  
                                                            Version 1.4, dated 30 -APR-2019  
                                                             Version 2.0, dated 10-OCT-2019  
     Version 2.1, dated 29-OCT-2020  
     Version 2.2, dated 14 -FEB-2022  
  
Keywords:  DNA repair; BAP1; PARP inhibitor; niraparib; homologous repair deficiency; 
cholangiocarcinoma; renal cell carcinoma; uveal melanoma; mesothelioma  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UF-STO-ETI-001  14 February 2022 
3 of 92  
       CONFIDENTIAL   Version 2. 2  Table of Contents  
1. BACKGROUND & RATIONALE  ................................ ................................ .... 18 
1.1 Study Rationale  ................................ ................................ ................................ ...... 19 
1.1.1  Rational e to Study Uveal Melanoma, Mesothelioma, Renal Cell Carcinoma, 
and Cholangiocarcinoma in Cohort A  ................................ ............................  20 
1.1.2  Rationale to Study Other D NA Repair Pathway Deficiencies in Cohort B  .... 20 
1.1.3  Details Regarding Additional Genes of Interest  ................................ .............  21 
1.2 Background of Niraparib  ................................ ................................ ........................  24 
1.3 Safety of Niraparib  ................................ ................................ ................................ . 24 
Table 1: Treatment Discontinuation Due to Myelosuppression Adverse Events of 
Any Grade  ................................ ................................ ................................ ....... 25 
1.4 Efficacy of Niraparib  ................................ ................................ ..............................  25 
1.5 Overview of Non -Clinical Studies  ................................ ................................ .........  26 
1.6 Overview of Clinical Studies  ................................ ................................ .................  26 
1.6.1  Phase 1 Trials ................................ ................................ ................................ .. 26 
1.6.2  Phase III Trial  ................................ ................................ ................................ . 27 
Table 2 : Overview of Clinical Studies of Niraparib  ................................ ................  27 
1.7 Rationale for Regimen/Doses/Schedule  ................................ ................................ . 29 
2. OBJECTIVES  ................................ ................................ ................................ ..... 30 
2.1 Primary  ................................ ................................ ................................ ...................  30 
2.2 Secondary  ................................ ................................ ................................ ...............  30 
2.3 Exploratory  ................................ ................................ ................................ .............  30 
3. STUDY DESIGN  ................................ ................................ ................................ . 30 
3.1 Study Overview  ................................ ................................ ................................ ...... 30 
4. SELECTION O F SUBJECTS  ................................ ................................ ............  31 
4.1 Number of Subjects  ................................ ................................ ................................  31 
4.2 Inclusion Criteria  ................................ ................................ ................................ .... 31 
4.3 Exclus ion Criteria  ................................ ................................ ................................ ... 33 
4.4 Inclusion of Women and Minorities ................................ ................................ ....... 34 
5. REGISTRATION PROCEDURES  ................................ ................................ ... 34 
6. STUDY PROCEDURES  ................................ ................................ .....................  34 
6.1 Screening Evaluations (Days -21 to Day 0):  ................................ ..........................  35 
6.2 Baseline Treatment Evaluations (Day 1, Cycle 1):  ................................ ................  35 
UF-STO-ETI-001  14 February 2022 
4 of 92  
       CONFIDENTIAL   Version 2. 2  6.3 On-Treatment Evaluations (Day 15 ± 1 day, Cycle 1):  ................................ ..........  35 
6.4 On-Treatment Evaluations (Day 1 ± 1 day, Cycle 2 and every cycle following):  . 36 
6.5 End of Treatment (EOT) Evaluations  (within seven days of last study drug 
administration):  ................................ ................................ ................................ ...... 36 
6.6 Follow -up Evaluations (30 ± 3 days post EOT):  ................................ ....................  36 
6.7 Unscheduled Evaluations for Adverse Events:  ................................ ......................  37 
7. STUDY TREATMENT  ................................ ................................ ......................  38 
7.1 Treatment Schedule/Administration  ................................ ................................ ...... 38 
Table 3 : Niraparib Dosing  ................................ ................................ ........................  38 
7.2 Specific Supportive Care  ................................ ................................ ........................  38 
7.2.1 Concomitant Therapy  ................................ ................................ ......................  38 
7.2.2  Allowed Concomitant Therapy  ................................ ................................ ........  39 
7.2.3  Prohibited Concomitant Therapy  ................................ ................................ .... 39 
7.3 Dose Modifications  ................................ ................................ ................................  40 
Table 4: N iraparib Dose Modifications for Adverse Reactions  ...............................  40 
7.3.1  Non- Hematologic Toxicity  ................................ ................................ .............  41 
Table 5:  Niraparib Dose Modifications for Non -Hematologic Toxicities  ...............  41 
7.3.2  Hematologic Toxicity  ................................ ................................ ......................  41 
Table 6: Niraparib Dose Modifications for Hematologic Toxicities*  .....................  41 
7.4 Supportive Care Guidelines  ................................ ................................ ...................  43 
7.5 Other Considerations  ................................ ................................ ..............................  43 
8. TREATMENT DISCONTINUATION  ................................ .............................  43 
8.1 Removal of Subjects from Study  ................................ ................................ ...........  43 
8.2 Criteria for Study Treatment Discontinuation  ................................ ........................  43 
8.3 Replacement of Subjects  ................................ ................................ ........................  44 
9. BIOLOGICAL SPECIMENS AND CORRELATIVES  ................................ .. 44 
9.1 Source of Specimens  ................................ ................................ ..............................  44 
9.2 Tumor Analysis and Molecular Profiling  ................................ .......................  45 
9.3 Next Generation Sequencing  ................................ ................................ ...........  45 
9.4 Correlative Studies  ................................ ................................ ..........................  45 
Table 7:  Correlative Assessments by Cohort  ................................ ...........................  46 
9.2 Preparation, Shipment and Storage of Specimens  ................................ .................  46 
10. STUDY DRUG INFORMATION  ................................ ................................ ...... 47 
UF-STO-ETI-001  14 February 2022 
5 of 92  
       CONFIDENTIAL   Version 2. 2  10.1  Administration  ................................ ................................ ................................ . 47 
10.2  Packaging  ................................ ................................ ................................ ........  48 
10.3  Drug Supply  ................................ ................................ ................................ .... 48 
10.4  Storage, Handling and Dispensing  ................................ ................................ .. 48 
10.5  Contraindications  ................................ ................................ ............................  48 
10.6       Clinically Reported Adverse Reactions  ................................ ..........................  49 
11. ADVERSE EVENTS  ................................ ................................ ...........................  50 
11.1  Definition  ................................ ................................ ................................ ........  50 
11.1.1  Serious Adv erse Event  ................................ ................................ ..............  51 
11.1.2  Clarification of the difference in meaning between “severe” and 
“serious”  ................................ ................................ ................................ .........  52 
11.1.3  Non-Serious Adverse Event  ................................ ................................ ...... 52 
11.1.4  Period of Observation  ................................ ................................ ..............  52 
11.2  Documenting and Reporting of Adverse Events by Investigator  ....................  53 
11.2.1  Intensity of Adverse Events  ................................ ................................ ...... 54 
11.2.2  Action Taken with Study Drug  ................................ ................................ . 55 
11.2.3  Definition of Outcome  ................................ ................................ ..............  55 
11.3  Immediately Reportable Events  ................................ ................................ ...... 55 
11.3.1  Serious Adverse Events  ................................ ................................ ............  55 
11.3.2  Other Events Requiring Immediate Reporting  ................................ .........  56 
11.4  Suspected Unexpec ted Serious Adverse Reactions (SUSARs)  ......................  58 
11.4.1  SUSAR Distribution ................................ ................................ ..................  58 
11.4.2  Adverse Events of Special Interest (AESI)s  ................................ ..............  59 
11.4.3  Sponsor Reporting  ................................ ................................ ...................  59 
11.4.4  Reporting Product Quality Complaints for Niraparib  .............................  60 
11.4.5  IND Safety Reports Unrelated to this Trial  ................................ ..............  60 
12.0  STATISTICAL METHODS  ................................ ................................ ........  60 
12.1  Sample Size Determination  ................................ ................................ .............  60 
12.2  Analysis of Primary Endpoint  ................................ ................................ .........  61 
12.3  Analysis of Secondary Endpoints  ................................ ................................ ... 61 
12.4  Analysis of Exploratory Endpoints  ................................ ................................ . 62 
12.5  Analysis of Safety Data  ................................ ................................ ...................  62 
12.6  Interim Analysis  ................................ ................................ ..............................  62 
UF-STO-ETI-001  14 February 2022 
6 of 92  
       CONFIDENTIAL   Version 2. 2  13. DATA AND SAFETY MONITORING  ................................ ............................  62 
13.1  Data Integrity and Safety Committee  ................................ ..............................  62 
13.2  Site Monitoring  ................................ ................................ ...............................  64 
13.3  Principal Investigator Responsibilities  ................................ ............................  64 
14. EMERGENCY PROCEDURES  ................................ ................................ ........  64 
14.1  Emergency Contact  ................................ ................................ .........................  64 
14.2  Emergency Identification of Investigational Products  ................................ .... 64 
14.3  Emergency Treatment  ................................ ................................ .....................  65 
15. ADMI NISTRATIVE, ETHICAL, AND REGULATORY 
CONSIDERATIONS  ................................ ................................ ..........................  65 
15.1  Good Clinical Practice  ................................ ................................ ....................  65 
15.2  Institutional Review Board ................................ ................................ ..............  65 
15.3 Compliance with Laws and Regulations  ................................ .........................  66 
15.4  Delegation of Investigator Responsibilities  ................................ ....................  66 
15.5  Subject Information and Informed Consent  ................................ ....................  66 
15.6  Confidentiality  ................................ ................................ ................................ . 67 
15.7  Protocol Amendments  ................................ ................................ .....................  67 
15.8  Case Report Forms  ................................ ................................ ..........................  67 
15.9  Record Retention  ................................ ................................ .............................  68 
15.10 Sub -Site Management and Communication Plan ................................ ................  68 
16. REFERENCES  ................................ ................................ ................................ .... 70 
17. APPENDICES  ................................ ................................ ................................ ...... 76 
Appendix A: SCHEDU LE OF EVENTS  ................................ ................................ ...... 77 
Appendix B: ECOG PERFORMANCE STATUS SCALE  ................................ ..........  79 
Appendix C: RECIST GUIDELINES (VERSION 1.1)  ................................ ................  80 
Appendix D: SUBJECT PILL DIARY  ................................ ................................ .........  87 
18. SUMMARY OF CHANGES  ................................ ................................ ...............  88 
 
  
  
  
 
UF-STO-ETI-001  14 February 2022 
7 of 92  
       CONFIDENTIAL   Version 2. 2  ABBREVIATIONS  
αKG  α-ketoglutarate  
AE Adverse Event  
AESI  Adverse Event of Special Interest  
ALT Alanine Transaminase (also SGPT)  
ANC  Absolute Neutrophil Count  
AST Aspartate Transaminase (also SGOT)  
AUC  Area Under Curve  
BER Base -Excision Repair  
BSA Body Surface Area  
BUN  Blood Urea Nitrogen  
CBC Complete Blood Count  
CE Carboxylesterases  
CL Clearance  
CLIA  Clinical Laboratory Improvement Amendments  
COSMIC  Catalogue of Somatic Mutations in Cancer  
CR Complete Remission  
CRF Case Report Form  
CRO  Clinical Research Office  
CT Computed Tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTMS  Clinical Trials Management System  
DDR  DNA Damage Response  
DISC  Data Integrity and Safety Committee  
DLT Dose -Limiting Toxicity  
DNA  Deoxyribonucleic Acid  
DSB Double -Strand Break  
DUB  Deubiquitinating  
ECG Electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
EOT End of Treatment  
FDG  Fluorodeoxyglucose Positron Emission  
FSH Follicle Stimulating Hormone  
GCP Good Clinical Practice  
GSK Glaxo Smith Kline  
HDPE  High -Density Polyethylene  
HR Homologous Recombination  
UF-STO-ETI-001  14 February 2022 
8 of 92  
       CONFIDENTIAL   Version 2. 2  HRD  Homologous Recombination Deficiency  
HRT Hormone Replacement Therapy  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IDH Isocitrate Dehydrogenase  
IHC Immunohistochemistry  
IR Ionizing Radiation  
IRB Institutional Review Board  
IV Intravenous  
kg Kilogram(s)  
LDH Lactic Dehydrogenase  
MCH  Mean Corpuscular Hemoglobin  
MCHC  Mean Corpuscular Hemoglobin Concentration  
MCV  Mean Corpuscular Volume  
MRI Magnetic Resonance Imaging  
MTD  Maximum Tolerated Dose  
NCI National Cancer Institute  
NGS  New Generation Sequencing  
NSAE  Non -Serious Adverse Event  
ORR  Objective Response Rate  
OS Overall Survival  
PARP  Poly ADP -Ribose Polymerases  
PCR Polymerase Chain Reaction  
PD Progressive Disease  
PMO        Project Management Office  
PET Positron Emission Tomography  
PFS Progression Free Survival  
PI Principal Investigator  
PK Pharmacokinetics  
PR Partial Remission  
PS Performance Status  
PT Prothrombin Time  
PTT Partial Thromboplastin Time  
RBC Red Blood Cells  
RECIST  Response Evaluation Criteria In Solid Tumors  
RNA  Ribonucleic Acid  
RR Response Rate  
SAE Serious Adverse Event  
UF-STO-ETI-001  14 February 2022 
9 of 92  
       CONFIDENTIAL   Version 2. 2  SD Stable Disease  
SGOT  Serum Glutamic Oxaloacetic Transaminase (also AST)  
SGPT  Serum Glutamic Pyruvate Transaminase (also ALT)  
SSB Single Strand Break  
SUSAR  Suspected Unexpected Serious Adverse Event  
Tmax  Time to Maximum Plasma Concentration  
TEAE  Treatment Emergent Adverse Event  
TMZ  Temozolomide  
UF University of Florida  
UFHCC  University of Florida Health Cancer Center  
UGT  University of Florida Health Cancer Center  
ULN  UDP -Glucuronosyltransferases  
US Upper Limit of Normal  
VUS United States  
WBC  Variants of Unknown Significance  
WHO  White Blood Cell  
WOCBP  World Health Organization  
UF-STO-ETI-001  14 February 2022 
10 of 92  
       CONFIDENTIAL   Version 2. 2  Site Protocol Signature Page  
 
A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and other DNA Damage Response 
(DDR) Pathway Deficient Neoplasms  
Study Principal 
Investigator:  
 
 
 
 
 
 
 
 
 
 
 
Local Principal 
Investigator:  
   
   
 Signature of Investigator  
 
  Date   
 
 
 Printed  Name of Investigator  
 
   
 Name of Facility  
 
   
 
 
 Location of Facility (City/State)  
 
_____________________________  
Signature of Investigator  
 
_____________________________  
Printed Name of Investigator  
 
_____________________________  
Name of Facility  
 
_____________________________  
Location of Facility (City/State)  
  
 
  
 
__________________  
Date  
 By my signature, I agree to personally supervise the conduct of 
this study and to ensure its conduct in compliance with the 
protocol, informed consent, IRB procedures, the Declaration of 
Helsinki, ICH Good Clinical Practices guidelines, and the 
applicable parts of the United States Code of Federal Regulations 
or local regulations governing the conduct of clinical studies.  
 
 
  
UF-STO-ETI-001  14 February 2022 
11 of 92  
       CONFIDENTIAL   Version 2. 2  STUDY SCHEMA  
 
Cohort A (n=35)  
 
Disease status assessed every 8 weeks  and continued until progression or unacceptable toxicity  
 
Cohort B (n=12)  
 
Δ If subjects baseline body weight is < 77kg (170 pounds) or baseline platelet count is < 
150,000/µl starting dose of 200 mg daily will be administered  
 
*ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, 
FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA -PK), PTEN, 
RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC  
 
Accrual Goal: 47 total subjects  
 
 
 
 
 Niraparib 300 mg daily on each day 
of a 28 -day cycle Δ  Histologic diagnosis of 
mesothelioma, uveal 
melanoma, renal cell 
carcinoma or 
cholangiocarcinoma . 
Confirmed histologic 
diagnosis of malignancy AND 
known somatic mutation 
(suggesting a loss of function) 
of component of the DNA 
damage repair pathway.*  Niraparib 300 mg daily on each day 
of a 28-day cycle Δ  
UF-STO-ETI-001  14 February 2022 
12 of 92  
       CONFIDENTIAL   Version 2. 2  PROTOCOL SYNOPSIS  
Title:  A Phase II Trial of the PARP Inhibitor,  Niraparib, in BAP1 and other DNA 
Damage Response (DDR) Pathway Deficient Neoplasm s  
Funding Organization:  TESARO /GSK  
Investigational Agent 
Supplier:  TESARO /GSK  
Rationale:  BAP1 is an  ubiquitin ligase that is critical in helping to regulate the cell 
cycle, cellular differentiation, cell death, and DNA damage response. This 
protein also acts as a tumor suppressor as highlighted with the 
hereditary cancer syndrome associated with germlin e mutations in the 
gene harboring BAP1.  
 
Most relevant to our study is BAP1s association with DNA damage 
response/repair. As BAP1s (BRCA1 Associated Protein 1) name implies it 
is intimately involved with double stranded DNA break repair. This 
protocol aims  to exploit the concept of synthetic lethality with the use 
of niraparib, an inhibitory of Poly -ADP Ribose Polymerase (PARP). Along 
these lines, this protocol is going to include tumors known to harbor 
BAP1 mutations (cohort  A) as well as tumors with alter ations in the DNA 
damage response (DDR) pathway (cohort B). The subjects of interest 
would have exhausted all standard lines of therapy and therefore this 
study would fill a significant medical need.  
Objectives:  Primary:  
• To determine the objective response rate (ORR) for subjects with 
BAP1 and other DDR repair pathway deficiencies  treated with 
niraparib . 
 
Secondary:  
• To determine the median progression free survival (PFS) and 
estimate PFS at 3 and 6 months  in each cohort and histologic 
subsets of sub jects. To estimate the median overall survival (OS)  
• To determine the incidence, severity, and reversibility of toxicities 
in subjects treated with niraparib.  
 
Exploratory:  
• To explore the impact that specific DNA repair mechanism 
deficiencies have on tumor P ARP inhibition  
• To explore alternate biomarkers that predict response to PARP 
inhibition  
UF-STO-ETI-001  14 February 2022 
13 of 92  
       CONFIDENTIAL   Version 2. 2  Study Design:  This is a prospective, open -label phase II study in two biologically 
distinct cohorts . 
Accrual Goal:  A total of 47 subjects (Cohorts A and B ). 
Cohort A:  35 subjects  in histologies that enrich for  BAP1 mutations  
Cohort B: 12 subjects  with any histology containing a pre -specified DNA 
DDR repair mutation  
Optional Cohort A expansion  within each  specific histology  
Inclusion Criteria:  Individuals eligible for study participation must meet the following 
criteria:  
A. Must be ≥ 18 years of age  
B. A clinical diagnosis of incurable cancer confirmed histologically.  
C. (For Cohort A) Must have confirmed diagnosis consistent with 
uveal melanoma, mesothelioma, renal cell carcino ma (clear cell 
subtype), or cholangiocarcinoma.  
D. (For Cohort B) Must have a pre -specified DNA DDR repair 
mutation including any one of the following: ARID1A, ATM, ATR, 
BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, 
ERCC, FAM175A, FEN1, IDH1, IDH 2, MRE11A, NBN (NBS1), 
PALB2, POLD1, PRKDC (DNA -PK) PTEN, RAD50, RAD51, RAD52, 
RAD54, RPA1, SLX4, WRN, or XRCC. Only CLIA certified next 
generation sequencing (NGS) assays are acceptable. Variants of 
unknown significance (VUS) will be allowed to enroll on study. 
Cohort B enrollment is histology agnostic.  
E. Must have formalin -fixed paraffin embedded (FFPE) tissue 
available for research purposes. Tissue must have been obtained 
within the last 3 years from a core or excisional biopsy.  
F. Measurable disease by RECIS T (v 1.1) criteria (prior radiation 
therapy to any indicator lesion must have demonstrated 
progressive growth of the lesion to be considered measurable).  
G. Adequate organ function as defined as:  
• Absolute neutrophil count (ANC) ≥ 1,500/ µL 
• Hemoglobin ≥ 9g/dL  
• Platelets ≥ 100,000/ µL 
• Total bilirubin ≤ 1.5 ULN or direct bilirubin ≤ 1 x ULN  
• Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) ≤ 2.5 x ULN; if liver metastases 
present, then AST and ALT must be ≤ 5 x ULN  
• Serum creatinine ≤ 1.5 x ULN or calculated creatinine 
clearance ≥ 60 mL/min using Cockcroft -Gault equation  
H. A medical history with prior exposure to standard systemic 
therapy (having exhausted or declined all known and currently 
UF-STO-ETI-001  14 February 2022 
14 of 92  
       CONFIDENTIAL   Version 2. 2  approved effective life prolonging therapies).  
I. An ECOG Perfo rmance Status less than or equal to 1.  
J. A life expectancy of greater than or equal to 12 weeks.  
K. Written informed consent obtained from the subject and the 
ability for the subject to comply with all the study -related 
procedures.  
L. Women of childbearing potenti al (WOCBP) must have a negative 
serum or urine pregnancy test within 7 days prior to the first 
dose AND be using an adequate method of contraception to 
avoid pregnancy throughout the study and for at least 180 days 
after the last dose of study drug to mini mize the risk of 
pregnancy. An adequate method of contraception is defined as 
contraceptive methods with a failure rate of less than 1% per 
year when used consistently and correctly. Subjects and their 
sexual partners who have undergone a vasectomy or tuba l 
occlusion must also use a male condom with spermicide. Prior to 
study enrollment, women of childbearing potential must be 
advised of the importance of avoiding pregnancy during trial 
participation and the potential risk factors for an unintentional 
pregn ancy.  
WOCBP include any woman who has experienced menarche and 
who has not undergone successful surgical sterilization 
(hysterectomy, bilateral tubal ligation, or bilateral 
oophorectomy) or who is not post -menopausal.  
Post -menopause is defined as:  
Amenorr hea that has lasted for ≥ 12 consecutive months without 
another cause, or for women with irregular menstrual periods 
who are taking hormone replacement therapy (HRT), a 
documented serum follicle -stimulating hormone (FSH) level of 
greater than 35 mIU/mL.  
M. Males with female partners of child -bearing potential must agree 
to use physician -approved contraceptive methods (e.g., 
abstinence, condoms, vasectomy) throughout the study and 
should avoid conceiving children for 180 days following the last 
dose of study dr ug. In addition, men must not donate sperm 
during niraparib therapy and for 180 days after receiving the last 
dose of niraparib.  
N. Subjects must agree to not donate blood during the study or for 
90 days after the last dose of study treatment.  
O. Subjects receiv ing oral corticosteroids may continue as long as 
their dose is stable for least 4 weeks prior to initiating protocol 
UF-STO-ETI-001  14 February 2022 
15 of 92  
       CONFIDENTIAL   Version 2. 2  therapy.  
P. If a new biopsy is needed for diagnostic reasons, the biopsy must 
be performed from a tumor site that is not the only site of 
measurable disease.  
Exclusion Criteria:  Subjects with any of the following will not be eligible for study 
participation:  
A. A medical history of prior exposure to PARP inhibitors (olaparib, 
niraparib, rucaparib, etc.).  
B. Subject has received or is planning to receive live vaccines within 
30 days prior to the first dose of trial treatment and while 
participating in the trial.  
C. A medical history demonstrating a BRCA1 or BRCA2 mutation.  
D. A pathologic diagnosis of prostate cance r as the cancer to be 
treated  in cohort B . 
E. Subject is simultaneously enrolled in any other interventional 
clinical trial.  
F. Subject has had major surgery ≤ 3 weeks of enrollment, and 
subject must have recovered from any effects of any major 
surgery.  
G. Subject has had investigational therapy administered ≤ 4 weeks, 
or within a time interval less than at least 5 half -lives of the 
investigational agent, whichever is longer, prior to the first 
scheduled day of dosing in this study.  
H. Subject has had radiotherapy enco mpassing > 20% of the bone 
marrow within 4 weeks of the first dose.  
I. Subject has a known hypersensitivity to the components of 
niraparib or the excipients.  
J. Subject received a transfusion (platelets or red blood cells) ≤ 4 
weeks of the first dose of study treatment.  
K. Subject has received colony stimulating factors (e.g., granulocyte 
colony -stimulating factor, granulocyte macrophage colony 
stimulating factor, or recombinant erythropoietin) within 4 
weeks prior to initiating protocol therapy.  
L. Subject has more than one active malignancy at the time of 
enrollment (Subjects with a prior or concurrent malignancy 
whose natural history or treatment does not have the potential 
to interfere with the safety or efficacy assessment of the 
investigational regimen [as deter mined by the treatment 
physician and approved by the PI] may be included).  
M. Subject has known, active symptomatic brain or leptomeningeal 
metastases.  
UF-STO-ETI-001  14 February 2022 
16 of 92  
       CONFIDENTIAL   Version 2. 2  N. Subject has had any known Grade 3 or 4 anemia, neutropenia or 
thrombocytopenia due to prior chemotherapy th at persisted > 4 
weeks and was related to the most recent treatment.  
O. Subject has any known history of myelodysplastic syndrome 
(MDS) or acute myeloid leukemia (AML).  
P. Females or males of childbearing potential who are unwilling or 
unable to use an acceptabl e method to avoid pregnancy for the 
entire study period and for at least 180 days after the last dose 
of study drug.  
Q. Females who are pregnant or breastfeeding.  
R. History of any other disease, metabolic dysfunction, physical 
examination finding, or clinical l aboratory finding giving 
reasonable suspicion of a disease or condition that 
contraindicates the use of protocol therapy or that might affect 
the interpretation of the results of the study or that puts the 
subject at high risk for treatment complications, in the opinion of 
the treating physician or study PI.  
S. Prisoners or subjects who are involuntarily incarcerated.  
T. Subjects who are compulsorily detained for treatment of either a 
psychiatric or physical illness.  
U. Subjects demonstrating an inability to comply with the study 
and/or follow -up procedures.  
Efficacy Assessments:  RECIST (version 1.1) and laboratory evaluations  
Statistical 
Considerations:  The sample size of 35 patients from Cohort A is based on a Simon optimal 
two stage design (one -sided alpha 0.05;  Beta 0.10) to increase the 
response rate from baseline <10% (H0) to 30% (H1) in this histologically 
selected patient population. The second stage of the study will proceed 
to 35 total patients if 3 or more patients from the first 18 enrolled have 
an objec tive response. If 7 or more patients respond among the 35, 
Cohort A treatment will be considered a success. The sample size of 12 
patients from Cohort B is based on an increase in the response r ate from 
baseline <10% (H0) to 5 0% (H1) in this molecularly se lected/enriched 
patient population (one -sided alpha 0.05; Beta 0.10). If 5 or more 
patients respond among the 12, Cohort B treatment will be considered 
a success. Cohort A and B success will be assessed independent of one 
another.  
 
Thus, a total sample siz e of 47 patients is proposed.  
 
Optional Cohort Expansion: In Cohort A only, independent of the final RR 
for the  entire cohort, if the ORR is >3 0% (H1) within any one of the 
UF-STO-ETI-001  14 February 2022 
17 of 92  
       CONFIDENTIAL   Version 2. 2    histology categories required for eligibility (i.e., mesothelioma alone), an 
expans ion cohort of an additional 20 patients (to obtain 18 evaluable) of 
that specific histology will be considered. This can be performed for each 
of the four histologies defined in Cohort A. This provides 80% power to 
determine this degree of activity.  
Estimated Enrollment 
Period:  30 months  
Estimated Study 
Duration:  Enrolled study participants will continue on study for a pproximately 8 
weeks, unless otherwise clinically indicated, before tumor status is 
assessed radiographically.  Total study duration is dependent on imaging 
studies (i.e. stable disease, progression, or response) and/or subject 
tolerability of study drug.  
UF-STO-ETI-001  14 February 2022 
18 of 92  
       CONFIDENTIAL   Version 2. 2  1. BACKGROUND & RATIONALE  
 
BAP1s Role in DNA Repair  
 
The post -translational modification of DNA repair proteins is essential for their function. This 
includes the addition or removal of ubiquitin. The covalent binding of ubiquitin to proteins can 
serve as a targeting signal, can modify protein activity, or a ffect its half -life1. Protein 
ubiquitination is linked to DNA damage signaling, DNA damage repair, and transcriptional 
silencing2 -14. BRCA1 is an ubiquitin ligase, and it ubiquitinates itself and other target proteins. 
This activity is balanced by deubiqui tinating (DUB) enzymes, which also interact with a variety of 
proteins during the repair of double -stranded breaks (DSB). One of these DUBs is BAP1 (BRCA1 
Associated Protein 1), which binds to the zinc finger moiety of BRCA1. First described in 1998, 
BAP1 is a 729 amino acid nuclear -localized protein that contains ubiquitin carboxy -terminal 
hydrolase activity15. BAP 1 also functions as a subunit of a multi -protein complex associated with 
regulating the cell cycle, cellular differentiation, cell death, and D NA damage responses12,16,17. 
BAP1 also increases the activity of BRCA1 3 -fold to 4 -fold, though it does not appear to directly 
modify BRCA1 itself16.  
 
Several lines of evidence also point to BAP1 as a tumor suppressor. The gene is located on 
chromosome 3p2 1.1. This is a region that is nearly universally deleted in small cell lung cancer, 
the vast majority of non -small cell lung cancers, as well as in some breast and renal cell 
carcinomas, among other malignancies18. Accompanying this loss of heterozygosity are a variety 
of inactivating mutations; affecting either one of the two nuclear localizing regions of the BAP1 
protein DUB catalytic site, or in some cases, epigenetic silencing of the BAP1 gene.  
 
Germline mutations in BAP1 are associated with an autosoma l-dominant hereditary cancer 
syndrome which is associated with an increased risk of developing uveal melanoma, 
mesothelioma, cutaneous melanocytic lesions, atypical Spitz tumors, and clear cell renal 
carcinomas. There also appears to be a less defined incr eased risk of meningiomas, lung 
adenocarcinomas, and neuroendocrine carcinomas.  
 
PARP inhibition and BAP1 Deficiency  
 
Poly  (ADP -ribose) polymerases (PARP -1 and -2) are nuclear proteins that contain three functional 
domains19, the most relevant to our study  is the two zinc fingers which are important for the 
binding of PARP1 to single -stranded and double -stranded DNA breaks20. When a single - strand 
DNA break occurs PARP binds to the end of the broken DNA strand. Once activated, PARP 
catalyzes the addition of  long polymers of ADP -ribose on several proteins associated with 
chromatin, including histones and various DNA repair proteins (including PARP). This results in 
chromatin relaxation, recruitment of DNA repair proteins and repair of DNA breaks. PARP is 
cruc ial in sensing DNA damage and signaling base -excision -repair (BER) and single strand  break 
UF-STO-ETI-001  14 February 2022 
19 of 92  
       CONFIDENTIAL   Version 2. 2  (SSB) repair pathways. Unrepaired SSBs, by way of PARP inhibition, move through DNA 
replication (S phase) and when a replication fork is reached the SSB will become a DSB21.  
 
A classic example of the importance of PARP activity in DNA DSB repair is breast cancer gene 
(BRCA) -1 and BRCA2 - deficient cells. BRCA is critical for HR in cells and these cells become 
“addicted” to other pathways of DNA repair (i.e. PARP and BE R) to allow for continued replication 
and survival. This concept of loss or inhibition of a gene, and its product, that the cell relies on to 
compensate for another gene loss causing the cell’s subsequent demise is referred to as synthetic 
lethality21,22. It has been proven in the lab that cells that are deficient in HR (i.e.  BRCA deficient) 
are hypersensitive to PARP inhibition23,24. There is also good evidence of the clinical efficacy of 
PARP inhibition in the setting of subject s with BRCA mutations. The PARP inhibitor olaparib was 
approved by the Food and Drug Administration (FDA) in December of 2014 for treatment of 
refractory (≥ 3 lines of therapy) ovarian cancer which harbors a BRCA 1/2 mutation.  In this select 
population results showed an objective r esponse rate of 34% and duration of response of 7.9 
months. Another PARP inhibitor, rucaparib, was recently approved for the same indication. 
Additionally, the PARP inhibitor, niraparib, was approved by the FDA in March of 2017 for the 
maintenance treatmen t of the adult population with recurrent epithelial ovarian, fallopian tube, 
or primary peritoneal cancer in individuals who are in complete or partial response to platinum -
based chemotherapy.  
 
Lab work at the University of Florida (Hromas, personal commun ication and data on file) was 
done to determine if synthetic lethality applies to BAP1 mutant cancers. Olaparib was given to 
BAP1 -mutant mesothelioma, H -Meso 001A, cells in clonogenic assays. Olaparib demonstrated 
significant cytotoxic activity with nearly  90% cell kill. The same cell line, but with loss of function 
mutations in ATM, Ligase III or ERCC4 (all components of the DNA DSB repair pathway) were 
treated with olaparib and synthetic lethality (70 -90% cell kill) was again exhibited. Taken 
together, it  is postulated that PARP inhibition with niraparib will result in significant 
cytoreduction in tumors that lack functional BAP1, as well as other deficiencies of the DNA 
damage repair pathway.  
 
1.1 Study Rationale  
 
This protocol will evaluate the PARP inhibito r, niraparib, in a phase II open label study that aims 
to exploit the concept of synthetic lethality in subject s with tumors known to potentially harbor 
BAP1 mutations (cohort A) and tumors with a known somatic gene mutation involved  in DNA 
damage pathway repair (cohort B).  
 
 
 
UF-STO-ETI-001  14 February 2022 
20 of 92  
       CONFIDENTIAL   Version 2. 2  1.1.1  Rationale to Study Uveal Melanoma, Mesothelioma, Renal Cell Carcinoma, and 
Cholangiocarcinoma in Cohort A  
 
Functionally, BAP1 appears to be required for cell genomic stability and survival following DNA 
damage. Several lines of pre-clinical evidence conducted by University of Florida investigators 
(Hromas, personal communication and data on file) support this line of scientific pursuit.  BAP1 
activation through phosphorylation on serine 592 is enhanced by cellular exposure to ion izing 
radiation (IR) in U2OS and HEK293 cell lines. This BAP1 phosphorylation  is significantly diminished 
or completely absent after the addition of caffeine which inhibits ATM/ATR kinases. A number of 
DNA damaging agents; including etoposide, cisplatin, a nd hydroxyurea also induce BAP1 
phosphorylation. To confirm that BAP1 regulates the stability of key homologous recombination 
(HR) components, studies have demonstrated that two distinct BAP1 siRNAs resulted in 
instability of RNF168, an E3 ubiquitin -protei n ligase required for accumulation of DNA repair 
proteins, with and without IR. The RNF168 protein level instability in BAP1 depleted cells is 
reversed by a proteasome inhibitor (MG132) again with and without IR. After depletion of BAP1 
in the dual reporte r cell line, HR was significantly impaired with identification of BAP1 co -
localizing with the p53 binding protein in ionizing irradiation -induced foci, which mark DNA DSBs. 
Thus, BAP1 appears required for proper DNA DSB repair in the HR pathway.  
 
Somatic m utations of BAP1 resulting in loss of expression or function have been reported in up 
to 47% of uveal melanomas, 23% of mesotheliomas, 15% of clear cell renal cell carcinomas, and 
in 26% of intrahepatic cholangiocarcinomas25 -28. Inclusion of these histolog ies in Cohort A will 
enrich for tumors with BAP1 deficiencies and support the testing of this clinical hypothesis.  Thus, 
cohort A serves as a means to determine whether BAP1 mutations confirm PARP activity 
regardless of histology. BAP1 status will be deter mined post -hoc for verification, but will use the 
histology defined here as a surrogate to enrich for this biomarker.  
 
1.1.2  Rationale to Study Other DNA Repair Pathway Deficiencies in Cohort B  
 
We have strategically chosen a number of DNA pathway repair g enes and their respective gene 
products to investigate prospectively in cohort B. The rationale is the same as with BAP1 in terms 
of inducing synthetic lethality with the combination of PARP inhibition. These genes of interest 
include ARID1A, ATM, ATR, BAC H1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, 
ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA -PK), PTEN, 
RAD50, RAD51, RAD52, RAD54, RPA1, SLX4,  WRN, or XRCC. Each of these genes is responsible for 
a component of the  DNA damage repair process (see section 1.2.3). Thus, a mutation resulting in 
loss of function of one of these genes could also provide susceptibility to PARP inhibition similar 
to the way proposed for BAP1 (i.e., synthetic lethality). However, these genet ic abnormalities are 
infrequent in the cancer patient population. This protocol will also retrospectively assess tumors 
in cohort A for non -BAP1 deficiencies in DNA damage repair. Cohort B enrollment is histology 
agnostic.  
UF-STO-ETI-001  14 February 2022 
21 of 92  
       CONFIDENTIAL   Version 2. 2  There is also recent evidence that isocitrate dehydrogenase (IDH) 1/2 mutations account for 
defects in HR29. The normal conversion of isocitrate to α -ketoglutarate (αKG) is mediated by IDH. 
With IDH mutations, αKG is aberrantly converted to the oncometabolite 2 - hydroxyglutarate 
(which  exists in two enantiomers). This oncometabolite was found to directly inhibit α -
ketoglutarate -dependent dioxygenases, which in turn caused HR suppression. The investigators 
were also able to show that IDH1 dependent HR deficiency conferred synthetic letha lity with 
PARP inhibition. Given these findings, we are also including IDH 1/2 mutations for cohort B 
eligibility to assess this proof of principle.  
 
Given the infrequent mutations and heterogenous histologic tumor types proposed in Cohort B, 
we are planni ng descriptive assessments of any response as a proof of principle to justify further 
testing in later studies.  
 
1.1.3  Details Regarding Additional Genes of Interest  
 
ARID1A (AT -rich Interactive Domain 1A)  
Encodes a protein that is a member of the SWI/SNF chromatin -remodeling complex.  ARID1A is 
recruited to DNA DSB via its interaction with ATR. It facilitates processing of DSB to single - 
strand ends. There is evidence that mutations in this gene can sensitize tumors to PARP 
inhibition30.  
 
ATM (Ataxia Telan giectasia Mutated)  
Encodes a kinase that is a member of the PI3 -kinase family.  ATM is critical in the early response 
to DNA damage (particularly DSBs)31. Activated ATM phosphorylates numerous other proteins 
(i.e. ATR, Chek1, Chek2) in response to DNA dama ge32.  
 
ATR (Ataxia Telangectasia and Rad3 -related)  
Encodes a kinase that is a member of the PI3 -kinase family. ATR is critical in the early response 
to DNA damage (as is ATM). ATR primary function is replication fork stability33. ATR is also 
important in r egards to regulating cell cycle by interacting with Chek1, Chek2, and ATM 32.  
 
BACH1 (BRCA1 Associated C -terminal Helicase)  
Also known as BRIP1, appears to be the gene product of the Fanconi Anemia gene, FANCJ. The 
helicase interacts with BRCA1 to assist in DNA DSB repair via HR 34.  
 
BAP1 (BRCA1 Associated Protein -1) See section 1.1  
 
BARD1 (BRCA1 Associated RING Domain 1)  
Encodes a protein that forms a heterodimer with BRCA1 and assists in early response to DNA 
damage. There is preclinical evidence of PARP  inhibition suppressing this association and 
impairing DNA repair.35  
UF-STO-ETI-001  14 February 2022 
22 of 92  
       CONFIDENTIAL   Version 2. 2  BLM (Bloom Syndrome RecQ Like Helicase)  
Encodes a helicase involved in DSB repair and HR. More specifically the protein assists in the 
repair and elimination of stalled replication forks during HR via an interaction with RAD5136.  
 
CHEK1 (Checkpoint Kinase 1)  
Encodes a kinase (called Chk1) that forms a complex with ATR and its function is critical with 
the DDR and cell cycle checkpoint response. The complex is activated in response to singl e- 
stranded DNA damage37.  
 
CHEK2 (Checkpoint Kinase 2)  
This gene encodes a kinase (called (Chk2) that forms a complex with ATM and helps coordinate 
DNA DSB repair. Chk2 also interacts and phosphorylates BRCA138.  
 
CDK2 (Cyclin -Dependent Kinase 2)  
Encodes a kinase that is essential for regulating cell cycle progression, specifically G1 to S. In 
response to DNA damage, CDK2 phosphorylates BRCA2 for DSB repair by homologous 
recombination39.  
CDK4 (Cyclin -Dependent Kinase 4)  
Encodes a kinase that is essential for  regulating cell cycle progression, specifically G1 to S phase. 
It acts in conjunction with CDK6 and cyclin D family and commits the cell to DNA synthesis.  
 
ERCC (Excision Repair Cross -Complementation) Encodes a helicase involved in nucleotide 
excision DNA  repair32.  
 
FAM175A (also known as Abraxas)  
Encodes protein involved in DSB repair by acting as a scaffolding protein to facilitate BRCA1 
binding40.  
 
FEN1 (Flap Endonuclease 1)  
Encodes a protein involved in single -stranded base excision DNA repair32.  
 
IDH1  (Isocitrate Dehydrogenase 1) See Section 1.2.2  
IDH2 (Isocitrate Dehydrogenase 2) See section 1.2.2  
 
MRE11A  
Encodes a protein that interacts with ATM and is involved detection and repair of DNA DSB via 
a complex with RAD50 and NBS1 (MRN). There is in vivo evidence of synthetic lethality with 
PARP inhibition in endometrial cancer cell lines41.  
 
 
 
UF-STO-ETI-001  14 February 2022 
23 of 92  
       CONFIDENTIAL   Version 2. 2  NBN (NBS1)  
Encodes a protein called nibrin that helps form MRN complex. Through interaction with ATM 
this complex helps with detection and repair of DNA DSB42.  
 
PALB2 (Partner and Localizer of BRCA2)  
Encodes a protein involved in DSB repair by binding and localizing with BRCA2. PALB2 binds the 
single strand DNA and directly interacts with the recombinase RAD51, an important step in  
homologous recombination. There is preclinical and clinical evidence (in prostate cancer) of 
PALB2 sensitivity to PARP inhibition43,44.  
 
POLD1 (Polymerase Delta 1)  
Encodes the catalytic subunit of Pol ᵟ which has a role in DNA DSB repair via HR45.  
 
PRKDC (Protein Kinase, DNA -Activated, C atalytic Polypeptide)  
Encodes the protein DNA -PK (DNA -dependent protein kinase) which belong to the PI3 -kinase 
family. The enzyme is required for non -homologous end joining (NHEJ) DNA DSB repair 46. 
Phosphorylation of substrates by DNA -PK induces recruitme nt of DSB proteins and activation of 
checkpoints 47. Synthetic lethality involving DNA -PK loss and various DDR proteins (e.g.  
ATM) has been observed in preclinical studies 48.  
 
PTEN (Phosphatase and Tensin Homolog)  
Encodes protein that is a potent tumor su ppressor. It is the central negative regulator of the 
PI3K/AKT pathway. Loss of PTEN causes increased AKT activation causing cellular 
proliferation49. PTEN interacts with RAD51 and RAD54 to assist in DNA DSB repair and 
homologous recombination. There is pr eclinical data of PTEN mutated cell lines exhibiting 
synthetic lethality when exposed to a PARP inhibitor50.  
 
RAD50  
Encodes protein which helps form MRN complex which is involved in detection and repair of 
DNA DSB42.  
 
RAD51  
Encodes protein that is one of f ive paralogs of RAD51 (RAD51B, RAD51C, RAD51D, XRCC2 and 
XRCC3). The paralogs are all required for DNA DSB repair. BRCA1/2, PALB2 and PTEN help 
RAD51 assembly on ssDNA, a key step in DNA DSB repair via HR51,52.  
 
RAD52  
Encodes protein that is involved in DN A DSB repair, specifically the 5’ to 3’ resection phase, via 
interaction with RPA and RAD51.  
 
 
UF-STO-ETI-001  14 February 2022 
24 of 92  
       CONFIDENTIAL   Version 2. 2  RAD54  
Encodes protein is a critical protein involved in HR, specifically branch migration and new DNA 
synthesis. It interacts with RAD51 to help stimulate DNA st rand exchange53.  
 
RPA1 (Replication Protein A1)  
Encodes protein that is involved in all modes of DNA repair. As it pertains to DSB repair, RPA 
interacts with RAD51 and RAD52 to assist in 5’ to 3’ resection and strand invasion. There is also 
evidence of int eraction with BRCA1 and BRCA254.  
 
SLX4  
Encodes protein that forms a multiunit complex involved in DNA DSB repair. This complex 
promotes cleavage of Holliday junctions at replication forks for single stranded annealing55.  
 
WRN (Werner Syndrome Helicase)  
Encodes protein that unwinds and separates DS DNA. The enzyme interacts with RAD51 to 
assist with DSB (HR, NHEJ) and BER repair56,57.  
 
XRCC  
A family of genes whose proteins are integrally involved in DSB DNA repair. XRCC2 and XRCC3 
form complexes with RAD5 1 to assist in HR. XRCC11 interacts with BRCA2 to assist in HR. XRCC4 
has direct interaction with LIG4 to assist in DSB ligation via NHEJ. XRCC5, XRCC6, and XRCC7 are 
involved in NHEJ by interacting with DNA -PK58.  
 
1.2 Background of Niraparib  
 
Niraparib is  an orally active PARP 1/2 inhibitor which targets tumors with defects in the HR repair 
pathway or tumors that are driven by PARP -mediated transcription factors. Niraparib 
demonstrates selective anti -proliferative activity for cancer cell lines that have b een silenced for 
BRCA -1 or BRCA -2 (or carry the mutation) compared to wild -type cell line. Niraparib causes cell 
cycle arrest in G2/M followed by apoptosis. The drug is also cytotoxic when evaluated in small 
cell lung cancer cell lines carrying homozygous inactivation of the ataxia telangiectasia mutated 
gene. In vivo studies demonstrated anti -tumor activity with BRCA -1 mutant breast cells, BRCA -2 
mutant pancreatic cancer, serous ovarian cancer, and xenograft models in mice.  
 
1.3 Safety of Niraparib  
 
Nirapa rib has low potential for drug -drug interactions in humans because it is a substrate of 
multiple metabolic enzymes including the significant involvement of the non -CYP (cytochrome 
P450) enzymes (i.e., carboxylesterases [CEs] and UDP -glucuronosyltransferase s [UGTs]).  
 
 
UF-STO-ETI-001  14 February 2022 
25 of 92  
       CONFIDENTIAL   Version 2. 2  There is phase 1, 2, and 3 data showing safety for niraparib. A Phase 1 clinical trial revealed the 
dose -limiting toxicity (DLT) for niraparib at 400 mg daily was thrombocytopenia59. The maximum 
tolerated dose (MTD) was determined to be 300 mg  daily. Drug -related toxicities at 300 mg, were 
grade 1 -2 (reversible), and included: anemia (48%), fatigue (42%), nausea (42%),  
thrombocytopenia (35%), anorexia (27%), neutropenia (24%), constipation (23%), and vomiting  
(20%).  
 
In the published phase 3 tr ial of ovarian cancer patients with niraparib the drug was found to be 
safe and tolerable60. Toxicities were very manageable with the most common grade 3 or 4 
toxicities being, thrombocytopenia (33.8%), anemia (25.3%), neutropenia (19.6%), and 
hypertension  (8.2%). Overall, 14.7% subject s who received niraparib discontinued the drug 
because of an adverse event. Most of the hematologic laboratory parameters occurred within 
the first three treatments. Treatment discontinuations were rare due to hematologic tox icity 
(Table 1).  
 
Table 1: Treatment Discontinuation Due to Myelosuppression Adverse Events of Any Grade  
 
Event  Niraparib (N=367)  Placebo (N=179)  
 no (%)  no (%)  
Thrombocytopenia  12 (3.3)  1 (0.6)  
Neutropenia  7 (1.9)  0 
Leukopenia  7 (1.9)  0 
Anemia  5 (1.4)  0 
Pancytopenia  3 (0.8)  0 
 
1.4 Efficacy of Niraparib  
 
In preclinical models, niraparib has been observed to inhibit normal DNA repair mechanisms and 
induce synthetic lethality when administered to cells with HR defects. In a BRCA1 mutant 
xenograft study, niraparib dosed orally caused tumor regression which was accompanied by  
>90% reduction in tumor weight compared to control. In a BRCA2 mutant xenograft study, 
niraparib dosed mice showed 55 -60% growth inhibition, both by tumor volume and weight. 
Niraparib is also selectively toxic for tumor cell lines carrying homozygous activation of the ATM 
gene. Details can be found in the Investigator’s Brochure.  
 
Anti-tumor activity was observed in the phase I studies taking niraparib as monotherapy at dose 
levels ranging from 60 to 400 mg. An overall response rate of 13% was observed for all subject s 
UF-STO-ETI-001  14 February 2022 
26 of 92  
       CONFIDENTIAL   Version 2. 2  in this study. Analysis of the 20 BRCA -mutant ovarian cancer patients showed a 35% overall 
response rate.  
 
A phase 3 randomized, double blind trial evaluated the ef ficacy of niraparib at 300 mg orally daily 
versus placebo as a maintenance treatment for subject s with platinum -sensitive, recurrent 
ovarian cancer60. Subjects were categorized according to the presence or absence of a germline 
BRCA mutation and then subse quently randomized to niraparib 300 mg orally or placebo in a 2:1 
fashion. Results revealed improved PFS in both the BRCA mutated group (21 vs 5.5 months) and 
non-BRCA group (9.3 vs 3.9 months). We will be using the same 300mg daily dose in our study.  
 
1.5 Overview of Non -Clinical Studies  
 
In non -clinical study models, niraparib treatment -related effects were observed (see Section 4.3 
of the Investigator’s Brochure Version 6.1). Niraparib was not considered mutagenic in Ames test, 
but was positive in 3 other genotoxicity assays (assay for DNA strand breaks in rat hepatocytes, 
CHO chromosomal aberrations assay and in vivo micronucleus assay of bone marrow cells).  
 
In the dog model, decreases in hematology values were observed during dosing, which resolved  
by the end of recovery. In the rat, mortality at the highest dose tested was considered to be due 
to septicemia likely due to cellular depletion of lymphoid organs and bone marrow.  
 
1.6 Overview of Clinical Studies  
 
An overview of clinical studies conduct ed for niraparib can be referenced in Table 2. For more 
details refer to the Investigator’s Brochure.  
 
1.6.1  Phase 1 Trials  
 
Niraparib has been administered to 144 patients  in the Phase 1 program. The most commonly 
reported (>20.0%) AEs (all grades, n = 144), were fatigue (58.3%), nausea (54.9%), anemia 
(50.7%), constipation (39.6%), thrombocytopenia (37.5%), vomiting (36.8%), decreased appetite  
(31.9%), neutropenia (28.5%),  headache (26.4%), diarrhea (21.5%), dyspnea (21.5%), cough  
(20.8%), and leukopenia (20.8%).  
 
The MTD was determined in Part A of Study PN001 to be 300 mg QD. Of note, the dose limiting 
toxicity of Grade 4 thrombocytopenia was observed in 2/6 subject s trea ted at the 400 mg QD 
dose level. Additionally, 1 subject  had a DLT of Grade 3 fatigue (30 mg QD) and 1 subject  had a 
DLT of Grade 3 pneumonitis (60 mg QD). The subject  who experienced pneumonitis had breast 
cancer involving the chest wall and had received prior radiation therapy, which involved exposure 
of lung to radiation. The pneumonitis did not have the sharp border representing the prior 
radiation port typical of recall pneumonitis. Since PARP inhibitors potentiate radiation damage in 
UF-STO-ETI-001  14 February 2022 
27 of 92  
       CONFIDENTIAL   Version 2. 2  nonclinical model s when given concurrently, it is possible that a PARP inhibitor could induce recall 
radiation pneumonitis. Two other subject s with breast cancer involving the chest wall who had 
received prior radiation therapy were subsequently treated and had no evidence  of pneumonitis.  
 
In PN001, 21 subject s treated at the MTD had AEs of thrombocytopenia reported (9 subject s 
Grade 1, 5 subject s had Grade 2, 4 subject s had Grade 3, and 3 subject s had Grade 4), 16 subject s 
experienced neutropenia (7 subject s Grade 1, 5 subjects Grade 2, and 4 subject s Grade 3), and 
34 subject s experienced anemia (5 subject s Grade 1, 21 subject s Grade 2, and 8 subject s Grade 
3). 
 
1.6.2  Phase III Trial  
 
In the published Phase 3 trial 31 utilizing single agent niraparib, the most common (>20%)  AEs 
were nausea (73.6.0%), thrombocytopenia (61.3%), fatigue (59.4%), anemia (50.1%),  
constipation (39.8%), vomiting (34.3%), neutropenia (30.2%), headache (25.9%), decreased  
appetite (25.3%), insomnia (24.3%) and abdominal pain (22.6%). The most common ( >10%)  grade 
3 or 4 AEs were thrombocytopenia (33.8%), anemia (25.3%) and neutropenia (19.6%). No 
subject s had a grade 3 or 4 bleeding event. Thrombocytopenia was transient and platelet levels 
stabilized beyond cycle 3.  
 
Table 2 : Overview of Clinical Studie s of Niraparib  
 
Protocol Number  Study Title  Status  
Phase 1  
PN001  A Phase 1 Study Of Niraparib In Patients With  
Advanced Solid Tumors Or Hematologic Malignancies  Completed  
PN005  A Phase 1 Study Of Niraparib In Patients With Solid  
Tumors  Terminated  
PN008  A Phase 1b Dose Escalation Study Of Niraparib In 
Combination With Carboplatin, Carboplatin/Paclitaxel  
And Carboplatin/Liposomal Doxorubicin In Patients 
With Advanced Solid Tumors  Terminated  
PN011  A Phase 1b Dose Escalation Study Of  Niraparib In 
Combination With Pegylated Liposomal Doxorubicin 
(Doxil™ Or Caelyx™) In Patients With Advanced Solid 
Tumors With A Cohort Expansion In Patients  
With Platinum -Resistant/Refractory High Grade Serous 
Ovarian Cancer.  Terminated  
UF-STO-ETI-001  14 February 2022 
28 of 92  
       CONFIDENTIAL   Version 2. 2  Protocol Number  Study Title  Status  
PN014  A Phase 1 S tudy Of Niraparib In Combination With 
Temozolomide (TMZ) In Patients With Advanced  
Cancer  Completed  
PR-30-5015 -C AME  Absorption, Metabolism, Excretion, and the 
Determination of Absolute Bioavailability of Niraparib  
in Subjects with Cancer  Ongoing  
64091742PCR1001  A Safety and Pharmacokinetics Study of Niraparib Plus 
Androgen Receptor -Targeted Therapy (Apalutamide or 
Abiraterone Acetate Plus Prednisone) in Men With  
Metastatic Castration -Resistant Prostate Cancer  Ongoing  
Phase 1/2  
3000 -PN162 -01-001 Phase 1/2 Clinical Study of Niraparib in Combination 
With Pembrolizumab in Patients With Advanced or 
Metastatic Triple -Negative Breast Cancer and in  
Patients With Recurrent Ovarian Cancer  Ongoing  
Phase 2  
PR-30-5020 -C A Phase 2, Open -Label, Single -Arm Study to Evaluate 
the Safety and Efficacy of Niraparib in Patients With 
Advanced, Relapsed, High -Grade Serous Epithelial 
Ovarian, Fallopian Tube, or Primary Peritoneal Cancer 
Who Have Received Three or Four Previous  
Chemot herapy Regimens  Ongoing  
64091742PCR2001  A Phase 2 Efficacy and Safety Study of Niraparib in 
Men With Metastatic Castration -Resistant Prostate  
Cancer and DNA -Repair Anomalies  Ongoing  
Phase 3  
PR-30-5010 -C BRAVO  A Phase III, Randomized, Open Label, Multicenter, 
Controlled Trial of Niraparib Versus Physician’s Choice 
in Previously -Treated, HER2 Negative, Germline BRCA 
Mutation -Positive Breast Cancer  
Patients  Ongoing  
PR-30-5011 -C A Phase 3 Randomized Double -Blind Trial of 
Maintenance With Niraparib Ve rsus Placebo in  
Patients With Platinum Sensitive Ovarian Cancer  Ongoing  
PR-30-5011 -C1- QTC QTc Sub -Study: A Phase 3 Randomized Double -Blind 
Trial of Maintenance With Niraparib Versus Placebo in  
Patients With Platinum Sensitive Ovarian Cancer  Ongoing  
UF-STO-ETI-001  14 February 2022 
29 of 92  
       CONFIDENTIAL   Version 2. 2  Protocol Number  Study Title  Status  
PR-30-5017 -C PRIMA  A Phase 3, Randomized, Double -Blind, Placebo - 
Controlled, Multicenter Study of Niraparib 
Maintenance Treatment in Patients With Advanced 
Ovarian Cancer Following Response on Front -Line 
Platinum -Based Chemotherapy  Ongoing  
PR-30-5011 -C2-FE FE Sub -Study: A Phase 3 Randomized Double -Blind 
Trial of Maintenance With Niraparib Versus Placebo in  
Patients With Platinum Sensitive Ovarian Cancer  Completed  
 
1.7 Rationale for Regimen/Doses/Schedule  
 
An analysis was conducted using the data collected in ENGOT -OV16/NOVA and the initial phase 
I study, PN001. This analysis determined that only baseline platelets had an impact on platelet 
nadir; lower baseline platelets (<180 109/L) were associated with an  increased frequency of 
thrombocytopenia Grade ≥1 (76%) or Grade ≥ 3 (45%) compared to subject s with higher baseline 
platelet counts. Further, an exploratory analysis of clinical data versus baseline body weight from 
ENGOT -OV16/NOVA was conducted. For this  analysis, the weight categories were based on 
quartiles with the lowest quartile ( subject s with a body weight less than 58 kg at  baseline) 
compared to the highest quartile ( subject s with a body weight greater than or equal to 77 kg at 
baseline). While TEA Es (added to list of abbreviations) occurred in most subject s regardless of 
body weight, Grade ≥3 TEAEs, SAEs, and TEAEs leading to dose modification or treatment 
discontinuation occurred more commonly in the weight <58 kg cohort than in the ≥77 kg cohort.  
In the cohort of subject s with a body weight <58 kg, approximately 80% of subject s had a dose 
reduction compared to 59% of subject s with a weight greater than or equal to 77 kg. Treatment 
discontinuations were increased in the subjects with lower body wei ght (24%) compared to 
subject s in the highest quartile (10%).  
The potential relationship between body weight and TEAEs was further explored in an analysis 
to evaluate the correlation of grade 3 or 4 thrombocytopenia and baseline body weight. The 
lowest pla telet count in the first 30 days was plotted versus baseline body weight to determine 
if low body weight identified a subgroup of subject s with higher levels of thrombocytopenia 
during Cycle 1. In the first 30 days of treatment, a baseline body weight >77 kg is associated with 
a lower incidence of grade 3 or 4 thrombocytopenia (14%) relative to the group with body weight  
<58 kg (43%).  
 
Finally, a classification tree approach was used to refine the best cut -off points for predicting the 
likelihood of a subje ct developing ≥Grade 3 thrombocytopenia within 30 days after the first dose 
of niraparib. The results of the model show that the subgroup of subject s with a baseline body 
weight <77 kg or baseline platelet count <150,000 µL had a grade 3/4 thrombocytopenia  rate in 
the first 30 days of 35.4% compared to 11.5% in the group of subject s with a body weight >77 kg 
and a platelet count >150,000 µL. Further, the average daily dose was 258 mg through the first 
UF-STO-ETI-001  14 February 2022 
30 of 92  
       CONFIDENTIAL   Version 2. 2  two cycles for subject s with a body weight >77 kg and pl atelet count >150,000 µL, and was only 
206 mg for subject s with body weight < 77 kg or platelet count <150,000 µL. Thus, the actual 
delivered dose approximated a starting dose of 200 mg despite the intended delivery of a starting 
dose of 300 mg. These obse rvations are to be confirmed in the present study with the inclusion 
of study treatment dosed at 200 mg (2 capsules of niraparib or placebo) in subject s whose 
baseline weight is <77 kg or baseline platelet count is <150,000 µL.  
 
The current clinical dose o f 300 mg daily (dry -filled capsules) was determined to be the MTD in 
early clinical testing (as above). This was also the dose given in the (490 -subject ) phase 3 
randomized, double -blind, placebo -controlled  trial (see toxicity above). Based on the above data 
subject s with weight < 77 kg or have a platelet count of < 150,000 µl in this trial will start at the 
200 mg daily dose.  
 
2. OBJECTIVES  
 
2.1 Primary  
• To determine the objective response rate (ORR) for sub jects with BAP1 and other DDR 
repair pathway deficiencies  treated with niraparib . 
 
2.2 Secondary  
• To determine the median progression free survival (PFS) and estimate PFS at 3 and 6 
months  in each cohort and histologic subsets of subjects.   PFS is defined as the duration 
of time from study entry to time of progression or death or the date of last contact, 
whichever occurs first.  
• To estimate the median overall survival (OS)  
• To determine the incidence, severity, and reversibility of toxicitie s in subjects treated 
with niraparib.  
 
2.3 Exploratory  
• To explore the impact that specific DNA repair mechanism deficiencies have on tumor 
PARP inhibition  
• To explore alternate biomarkers that predict response to PARP inhibition  
 
3. STUDY DESIGN  
 
3.1 Study Overview  
 
This is a prospective, open -label phase II trial  in two biologically distinct patient cohorts . A total 
of 47 subjects are planned. Each subject will be administered a daily dose of study drug during 
treatment cycles. Each cycle is twenty -eight (+/- 1) days in length. Study treatment will continue 
until the development of unacceptable toxicity, disease progression (radiographic assessment 
every 8 weeks), or participant desire to discontinue protocol therapy. Clinic evaluations will be 
UF-STO-ETI-001  14 February 2022 
31 of 92  
       CONFIDENTIAL   Version 2. 2  taken at base line, days 1 and 15 for the first cycle, and day 1 of each subsequent cycle (28 +/- 1 
days).   Screening data will be reviewed to determine subject eligibility. Subjects who meet all 
inclusion criteria and none of the exclusion criteria will be entered into  the study.  
 
The following treatment regimen will be used:  
• Both subject cohorts A and B will receive niraparib at 300 mg orally daily on each day of 
twenty -eight (+/-1) day cycle.  
• Enrolled study participants will continue on study for approximately  8 weeks, unless 
otherwise  clinically indicated, before tumor status is assessed radiographically. Total 
study duration is dependent on imaging studies (i.e. stable disease, progression, or 
response) and/or subject tolerability of study drug.  
 
4. SELECTION  OF SUBJECTS  
 
Subjects with a diagnosis of incurable cancer who meet the following inclusion and exclusion 
criteria will be eligible for participation in this study. In the event of a known BAP1 mutation in a 
histology included in Cohort A, assignment woul d be to Cohort A as BAP1 status will be eventually 
determined post -hoc.  
 
4.1 Number of Subjects  
 
A total of 47 subjects are to be enrolled with thirty -five subjects in Cohort A and twelve subjects 
in Cohort B.   Additionally, there is the possibility of further subject enrollment (a pre -specified 
optional expansion cohort of up to an additional 20 subjects [to obtain 18 evaluable ]) based on 
meeting a minimum ORR in each specific histolog y identified in Cohort A (See Section 12.1).  
 
4.2 Inclusion Criteria  
 
Individuals eligible for study participation must meet the following criteria:  
A. Must be ≥ 18 years of age  
B. A clinical diagnosis of incurable cancer confirmed histologically.  
C. (For Cohort A) Must have confirmed diagnosis consistent with uveal melanoma, 
mesothelioma, renal cell carcinoma (clear cell subtype), or cholangiocarcinoma.  
D. (For Cohort B) Must have a pre -specified DNA damage repair mutation including any 
one of the following: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, 
CHEK2, CDK2, C DK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, 
POLD1, PRKDC (DNA -PK), PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or 
XRCC. Only CLIA certified next generation sequencing (NGS) assays are acceptable. 
Variants of unknown significance  (VUS) will be allowed to enroll on study. Cohort B 
enrollment is histology agnostic.  
UF-STO-ETI-001  14 February 2022 
32 of 92  
       CONFIDENTIAL   Version 2. 2  E. Must have formalin -fixed paraffin embedded (FFPE) tissue available for research 
purposes. Tissue must have been obtained within the last 3 years  from a core or 
excisional  biopsy . 
F. Measurable disease by RECIST (v 1.1) criteria (prior radiation therapy to any indicator 
lesion must have demonstrated progressive growth of the lesion to be considered 
measurable ). 
G. Adequate organ function as defined as:  
• Absolute neutrophil count (ANC) ≥ 1,500/ µL 
• Hemoglobin ≥ 9g/dL  
• Platelets ≥ 100,000/ µL 
• Total bilirubin ≤ 1.5 ULN or direct bilirubin ≤ 1 x ULN  
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; if 
liver metastases present, then AST and ALT must be ≤ 5 x ULN 
• Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min using 
Cockcroft -Gault equation  
H. A medical history with prior exposure to standard systemic therapy (having exhausted 
or declined all known and currently approved effective life prolonging therapies).  
I. An ECOG Performance Status less than or equal to 1.  
J. A life expectancy of greater than or equal to 12 weeks  
K. Written informed consent obtained from the subject and the ability for the subject to 
comply with all the study -related proced ures.  
L. Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test within 7 days prior to the first dose AND be using an adequate method 
of contraception to avoid pregnancy throughout the study and for at least 180 days 
after the last dose of study drug to minimize the risk of pregnancy. An adequate method 
of contraception is defined as contraceptive methods with a failure rate of less than 1% 
per year when used consistently and correctly. Subjects and their sexual partners who  
have undergone vasectomy or tubal occlusion must also use a male condom with 
spermicide. Prior to study enrollment, women of childbearing potential must be advised 
of the importance of avoiding pregnancy during trial participation and the potential risk 
factors for an unintentional pregnancy.  
WOCBP include any woman who has experienced menarche and who has not 
undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or 
bilateral oophorectomy) or who is not post -menopausal. Post -menopausal defined as:  
Amenorrhea that has lasted for 12 consecutive months without another cause, or  for 
women with irregular menstrual periods who are taking hormone replacement therapy 
(HRT), a documented serum follicle -stimulating hormone (FSH) level o f greater than 35 
mIU/mL.  
M. Males with female partners of child -bearing potential must agree to use physician - 
approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout 
the study and should avoid conceiving children for 180 days follow ing the last dose of 
UF-STO-ETI-001  14 February 2022 
33 of 92  
       CONFIDENTIAL   Version 2. 2  study drug. In addition, men must not donate sperm during niraparib therapy and for 
180 days after receiving the last dose of niraparib.  
N. Subjects must agree to not donate blood during the study or for 90 days after the last 
dose of stu dy treatment.  
O. Subjects receiving  oral corticosteroids may continue as long as their dose is stable for 
least 4 weeks prior to initiating protocol therapy.  
P. If a new biopsy is needed for diagnostic reasons, the biopsy must be performed from a 
tumor site that  is not the only site of measurable disease.  
 
4.3 Exclusion Criteria  
 
Subjects with any of the following will not be eligible for study participation:  
A. A medical history of prior exposure to PARP inhibitors  (olaparib, niraparib rucaparib, 
etc.). 
B. Subject has received or is planning to receive live vaccines within 30 days prior to the 
first dose of trial treatment and while participating in the trial.  
C. A medical history demonstrating a BRCA1 or BCRA2 mutation.  
D. A pathologic diagnosis of prostate cance r as the cancer to be treated  in cohort B . 
E. Subject  is simultaneously enrolled in any other interventional clinical trial . 
F. Subject  has had major surgery ≤ 3 weeks of enrollment,  and subject  must have 
recovered from any effects of any major surgery . 
G. Subject   has had investigational therapy administered ≤ 4 weeks, or within a time 
interval less than at least 5 half -lives of the investigational agent, whichever is longer, 
prior to the first scheduled day of dosing in this study . 
H. Subject  has had radiotherapy e ncompassing > 20% of the bone marrow within 4 weeks 
of the first dose . 
I. Subject  has a known hypersensitivity to the components of niraparib or the excipients . 
J. Subject received a transfusion (platelets or red blood cells) ≤ 4 weeks of the first dose of 
study treatment . 
K. Subject has received colony stimulating factors (e.g., granulocyte colony - stimulating 
factor, granulocyte macrophage colony stimulating factor, or recombinant 
erythropoietin) within 4 weeks prior initiating protocol therapy . 
L. Subject has more than one active malignancy at the time of enrollment ( Subject s with a 
prior or concurrent malignancy whose natural history or treatment does not have the 
potential to interfere with the safety or efficacy assessment of the investigational 
regimen [as d etermined by the treatment physician and approved by the PI] may be 
included).  
M. Subject  has known, active symptomatic brain or leptomeningeal metastases . 
N. Subject has had any known Grade 3 or 4 anemia, neutropenia or thrombocytopenia due 
to prior chemothera py that persisted > 4 weeks and was related to the most recent 
treatment.  
UF-STO-ETI-001  14 February 2022 
34 of 92  
       CONFIDENTIAL   Version 2. 2  O. Subject  has any known history of myelodysplastic syndrome (MDS) or acute myeloid 
leukemia (AML) . 
P. Females or males of childbearing potential who are unwilling or unable to use an 
acceptable method  of birth control  to avoid pregnancy for the entire study period and 
for at least 180 days after the last dose of study drug.  
Q. Females who are pregnant or breastfeeding.    
R. History of any other disease, metabolic dysfunction, physical examination finding, or 
clinical laboratory finding giving reasonable suspicion of a disease or condition that 
contraindicates the use of protocol therapy or that might affect the interpretation of the 
results of the study or that puts the subject at high risk for treatment complications, in 
the opinion of the treating physician or study PI.  
S. Prisoners or subjects who are involuntarily incarcerated.  
T. Subjects who are compulsorily detained for treatment of either a psychiatric or physical 
illness.  
U. Subjects dem onstrating an inability to comply with the study and/or follow -up 
procedures.  
 
4.4 Inclusion of Women and Minorities  
 
Both men and women and members of all races and ethnic groups are eligible for this trial.  
 
5. REGISTRATION PROCEDURES  
 
All consented  subjects must entered into the University of Florida’s Clinical Trial Management 
System (OnCore) prior to assignment of a subject identification number.  This is not registration 
into the trial. The study team must submit the completed study specific elig ibility checklist, 
supporting source documentation and a copy of the signed informed consent document(s) to the 
UFHCC Project Management Office (PMO; PMO@cancer.ufl.edu) or their assigned Project 
Manager.  Unsigned eligibility checklists or eligibility pac kets with missing or incomplete 
information may be returned to the study team. Upon receipt of a completed eligibility packet, 
the designated Project Manager will review the source to verify eligibility and assign a subject 
number.  If eligibility cannot b e confirmed, the project manager will query the site for clarification 
or additional documents as needed. Subjects failing to meet all study eligibility requirements will 
not be able to participate in the trial.  
 
 
 
 
6. STUDY PROCEDURES  
 
UF-STO-ETI-001  14 February 2022 
35 of 92  
       CONFIDENTIAL   Version 2. 2  Please see the Sche dule of Events located in Appendix A.  
 
6.1 Screening Evaluations (Days -21 to Day 0):  
 
Written informed consent must be obtained prior to performing any study -specific evaluations 
or tests. Tests or evaluations performed as standard of care within the specified screening period, 
but prior to informed consent, may be accepted for this study and need not be repeated.  
 
The following pre -treatment measurements will be obtained within 21 days prior to the 
initiation of study therapy:  
• Height, weight and ECOG performance will be collected from each subject.  
• A complete medical history, toxicity assessment, and physical exam will be completed 
for each subject.  
• Blood and urine samples will be obtained for the following laboratory studies:  
o CBC with differential count  
o Comprehensive metabolic panel  
o Urine  or serum  pregnancy test (females of potential child -bearing status only)  
• CT or PET/CT scans, or MRI scans of the chest, abdomen, and pelvis will be obtained for 
tumor measurement (NOTE: baseline study imaging must be performed within 28 days 
prior to initiation of study therapy).   Imaging studies used at study entry to establish 
baseline tumor measurement(s) should be the imaging modalities used to monitor 
subsequent disease response.  
• Attainment and submission of previously obtained FFPE tissue (must have been 
obtained within last 3 years). If archival tissue is unavailable or inadequate, new biopsy 
must be obtained to confirm histology and molecular profile.  
 
6.2 Baseline Treatment Evaluations (Day 1, Cycle 1):  
 
• Height, weight and ECOG performance will be collected from each subject.  
• An interim medical history, toxicity assessment, and physical exam will be obtained from 
each subject.  
• Blood and urine samples will be obtained for the following laboratory studies:  
o CBC with differential count (Note: CBCs should be collected weekly during Cycle 
1. 
o Comprehensive metabolic panel  
o Urine or serum pregnancy test (females of potential child -bearing status only)  
o Research blood collection  
 
6.3 On-Treatment Evaluations (Day 15 ± 1 day, Cycle 1):  
 
UF-STO-ETI-001  14 February 2022 
36 of 92  
       CONFIDENTIAL   Version 2. 2  • Height, weight and ECOG performance status will be collected from each subject.  
• An interim medical history, toxicity assessment, and physical exam will be obtained from 
each subject.  
• Blood samples for a CBC with differential count and a c omprehensive metabolic panel 
will be obtained.  
• Research blood collection  
 
6.4 On-Treatment Evaluations (Day 1 ± 1 day, Cycle 2 and every cycle following):  
 
• Height, weight and ECOG performance will be collected from each subject.  
• An interim medical history,  toxicity assessment, and physical exam will be obtained from 
each subject.  
• Blood and urine samples will be obtained for the following laboratory studies:  
o CBC with differential count  
o Comprehensive metabolic panel  
o Urine or serum pregnancy test (females of potential child -bearing status only)  
o Research blood collection  
• Repeat imaging  will be obtained every 8 weeks (+/ - 7 days)  from first dose (Cycle 1 Day 
1) until disease progression or death to assess response.  
 
6.5 End of Treatment (EOT) Evaluations (within  seven days of last study drug 
administration):  
 
• Height, weight and ECOG performance status will be collected from each subject.  
• An interim medical history, toxicity assessment, and physical exam will be obtained from 
each subject.  
• Blood will be obtained f or the following laboratory studies:  
o CBC with differential count  
o Comprehensive metabolic panel  
o Research blood collection  
• A tumor biopsy will be done upon progression of disease (with subject’s permission) for 
research purposes . The timing of the research biopsy should be ideally within 7 days of 
the EOT visit or at least prior to the start of any subsequent anticancer therapy.  
• If feasible, the EOT visit, except for the biopsy noted in 6.5, should be performed within 
seven days regardless of the reason for discontinuation.  If the subject withdraws 
consent, however, no further study procedures can proceed.  
 
 
 
6.6 Follow -up Evaluations (30 ± 3 days  post EOT):  
UF-STO-ETI-001  14 February 2022 
37 of 92  
       CONFIDENTIAL   Version 2. 2   
• Height, weight and ECOG performance status will be collected from each subject.  
• An interim medical history, toxicity assessment, and physical exam will be obtained from 
each subject.  
• Blood samples for a CBC with differential count and a comprehensive metabolic panel 
will be obtained.  
• Research blood collection . 
 
Follow -up Evaluations should occur regardl ess of the reason for discontinuation.  If the subject 
withdraws consent, however, no further study procedures can proceed.  
 
Subjects will additionally be followed every three months for vital statistics and development of 
MDS/AML until death . If subjects are lost to follow -up, every effort will be made at least quarterly 
to attempt to locate the subject to obtain their health status.  
 
6.7 Unscheduled Evaluations for Adverse Events:  
 
• An interim medical history, toxicity assessment, and physical exam will be  obtained.  
• Blood will be obtained for laboratory evaluation at the treating physician’s discretion to 
support clinical workup.  
• If dose interruption or modification is required at any point on study because of 
hematologic toxicity, weekly blood draws for CB C will be monitored until the AE 
resolves, and to ensure safety of the new dose, weekly blood draws for CBC also will be 
required for an additional 4 weeks after the AE has been resolved to the specified levels, 
after which monitoring every 4 weeks may res ume.  
• If the chest CT or MRI is clear at screening, repeat chest imaging is not required in the 
absence of lesions to be followed or in the absence of clinical indication requiring 
follow -up; otherwise, repeat chest imaging should be completed at the same t ime as 
RECIST imaging.  
• For any suspected MDS/AML case reported while a subject is receiving treatment or 
being followed for post -treatment assessments, bone marrow aspirate and biopsy 
testing must be completed by a local hematologist. A whole blood sample will also be 
collected for cytogenetic analysis (mutations of select myeloid -associated genes). 
Testing completed as part of standard of care is sufficient as long as the methods are 
acceptable to the Principal Investigator . The study site must receive a c opy of the 
hematologist’s report of aspirate/biopsy findings (which must include a classification 
according to World Health Organization criteria) and other sample testing reports 
related to MDS/AML. The site must keep a copy of the report with the subject ’s study 
file. 
 
UF-STO-ETI-001  14 February 2022 
38 of 92  
       CONFIDENTIAL   Version 2. 2  7. STUDY TREATMENT  
 
All subjects entering the screening phase will receive a unique subject number. This number will 
be used to identify the subject throughout the study. Subjects withdrawn from the study will 
retain their subject number.  
 
7.1 Treatment Schedule/Administration  
 
Niraparib will be administered as a flat -fixed, continuous daily dose beginning at the baseline visit 
(Cycle 1/Day 1) according to the Table 3 below.  
 
Table 3: Niraparib Dosing  
 
Baseline Criteria  (weight and platelet count)  Starting Dose  
≥77 kg and  platelets  ≥150,000 µL  300 mg (3 X 100 mg capsules)  
<77 kg or  platelets  100, 000 -149,000  µL 200 mg (2 X 100 mg capsules) *  
 
*For subject s whose starting dose is 2 capsules once daily, escalation to 3 capsules once daily is 
required at the discretion of the treating provider at the beginning of cycle 3  ± 1 day , if no 
treatment interruption or discontinuation was required during the first 2 cycles of therapy , and 
the treating physician documents no other justification to maintain the lower dose.  
 
If tumor assessment done with diagnostic imaging demonstrates a decrease (i.e. partial 
response) or no change in tumor size (i.e. stable disease), s ubjects may continue on this 
niraparib regimen.  
 
7.2 Specific Supportive Care  
 
7.2.1  Concomitant Therapy  
 
Relevant medical history should be obtained at screening and include prior medications and 
treatment history. All medications taken within four weeks (or 28 days) prior to screening, 
regardless of indication, should be recorded.  
 
Any therapy or medication (except study drugs), administered from screening until thirty days 
after the last dose of either study drug, is considered a concomitant therapy or m edication.   
However, if another course of anti -cancer therapy is initiated prior to the thirty -day follow -up 
period visit; a record of concomitant medications will no longer be performed. If the use of any 
concomitant treatments (medications or procedures ) becomes necessary, the treatment must 
be recorded, including the name of the drug or treatment, dose, route, date, indication for use, 
UF-STO-ETI-001  14 February 2022 
39 of 92  
       CONFIDENTIAL   Version 2. 2  expected duration, and frequency of treatment. Assessment and documentation of concomitant 
medications will be done at each visit.  
 
7.2.2  Allowed Concomitant Therapy  
 
See protocol -specific supportive care information in Section 7.2. All other supportive measures 
consistent with optimal patient care will be given throughout the study.  
• Nausea: Anti -emetics should be administered per institutional guidelines.  
• Diarrhea: Subjects should be provided with instructions on use of loperamide (Imodium) 
in the event of diarrhea, as well as instructions to contact the treating physician. Other 
anti-diarrheals are also allowed. S ubjects should be given mouth care instructions per 
institutional guidelines.  
• Neutropenia: Prophylactic use of G -CSF or Peg -G-CSF is not permitted. Please refer to 
Table 4 for neutropenia adverse event guidelines.  
 
7.2.3  Prohibited Concomitant Therapy  
 
Subjects are prohibited from receiving the following therapies during the Screening and 
Treatment Phase of this trial:  
• Antineoplastic systemic chemotherapy or biological therapy  
• Immunotherapy not specified in this protocol  
• Chemotherapy not specified in this p rotocol  
• Investigational agents other than the study drug in this trial  
• Radiation therapy Radiation Therapy  
• Palliative radiation therapy (excluding the pelvic region and/or palliative radiotherapy 
encompassing > 20% of the bone marrow within 2 weeks of the first dose of study 
treatment) to a symptomatic solitary lesion may be considered on an exceptional case 
by case basis for pre - existing small areas of painful metastases that cannot be managed 
with local or systemic analgesics as long as no evidence of di sease progression is present 
after consultation with sponsor -investigator. The subject must have clear measurable 
disease outside the radiated field. Administration of palliative radiation therapy will be 
considered clinical progression for the purposes of  determining PFS.  
• Vaccines  
o Live vaccines are prohibited within 30 days prior to the first dose of trial treatment 
and while participating in the trial. Examples of live vaccines include, but are not 
limited to, the following: measles, mumps, rubella, chick en pox, yellow fever, rabies, 
BCG, and typhoid (oral) vaccine.  
o Seasonal influenza vaccines for injection are generally killed virus vaccines and are 
allowed. However, intranasal influenza vaccines (e.g. Flu - Mist®) are live attenuated 
vaccines, and are no t allowed.  
 
UF-STO-ETI-001  14 February 2022 
40 of 92  
       CONFIDENTIAL   Version 2. 2  • Substrates of P -glycoprotein  
o Niraparib is a substrate for P -glycoprotein (P -gp); therefore, subject s should be 
advised to use caution with drugs that are inhibitors of P -gp. The niraparib safety 
profile includes risk for thrombocytopenia; there fore, subject s should be advised 
to use caution with anticoagulation and antiplatelet drugs.  
• Blood Donation  
o Subject s must not donate blood during the study or for 90 days after the last 
dose of study treatment.  
 
7.3 Dose Modifications  
 
Treatment must be interrupted for any non -hematologic National Cancer Institute (NCI) 
Common Terminology Criteria for Adverse Events (CTCAE version 4.03, 
http://evs.nci.nih.gov/ftp1/CTCAE/Abou t.html ) grade 3 or 4 adverse event which the 
Investigator considers related to the administration of niraparib. If toxicity is appropriately 
resolved to baseline or grade 1 or less within 28 days, the subject  may restart treatment with 
niraparib, but with a dose level reduction according to Table 5. If event recurs at similar or 
worse grade, treatment should be interrupted again and upon resolution, a further dose 
reduction must be made. No more than 2 dose reductions will be permitted.  
 
If the toxicity req uiring dose interruption has not resolved completely or to NCI -CTCAE grade 1 
during the maximum 4-week  (28 day) dose interruption period, and/or the subject  has 
undergone a maximum of 2 dose reductions (to a minimum dose of 100 mg once daily), the 
subject  must permanently discontinue treatment with niraparib.  
 
For subject s whose dose is 3 capsules daily (300 mg/day), dose reductions to 2 capsules daily (200 
mg/day) and subsequently to 1 capsule daily (100 mg/day) will be allowed. No further dose 
reduction w ill be allowed.  
 
Table  4: Niraparib Dose Modifications for Adverse Reactions  
 
Dose level  Initial Dose: 3 capsules per day  Initial Dose: 2 capsules per day  
Starting dose  3 capsules once daily (300 mg/day)  2 capsules once daily (200 mg/day)  
First dose 
reduction  2 capsules once daily (200 mg/day)  1 capsule once daily (100 mg/day)  
Second dose 
reduction  1 capsule once daily (100 mg/day)  NA 
If initial starting dose was 200 mg/day but subsequently increased to 300 mg/day at cycle 3, 
dose reductions are to follow as if they started at 300 mg/day.  
 
UF-STO-ETI-001  14 February 2022 
41 of 92  
       CONFIDENTIAL   Version 2. 2  7.3.1  Non- Hematologic Toxicity  
 
Table 5: Niraparib Dose Modifications for Non -Hematologic Toxicities  
 
Event  Dose  
Non -hematologic CTCAE ≥ Grade 3 adverse 
reaction where prophylaxis is not considered 
feasible or adverse reaction persists despite 
treatment  • Withhold niraparib for a maximum of 28 days 
or until adverse reaction has  improved to < 
Grade 1.  
• Resume niraparib at a one dose level 
reduction per Table 4.  
CTCAE ≥ 3 treatment -related adverse 
reaction lasting m ore than  28 days while 
subject is administered niraparib 100 mg/day  Discontinue niraparib  
 
7.3.2  Hematologic Toxicity  
 
Table 6: Niraparib Dose Modifications for Hematologic Toxicities*  
 
Event  Dose Modification   
Monitor complete blood counts weekly for the first month, monthly for the next 11 months of 
treatment, and  periodically after this time.  
Platelet count < 100,000/µL  First occurrence:  
If platelet count is 75,000 -100,000/µL : 
• Withhold niraparib for a maximum of 28 days and 
monitor blood counts weekly until platelet counts 
return to ≥ 100,000/µL***  
• Resume niraparib at same or reduced dose per Table  4 
If platelet count is < 75,000/ µL : 
• Withhold niraparib for a maximum of 28 days and 
monitor blood counts weekly until platelet counts 
return to ≥ 100 ,000/µL***  
• Resume niraparib  at a reduced dose.  
Second occurrence:  
• Withhold niraparib for a maximum of 28 days and 
monitor blood counts weekly until platelet counts 
return to ≥ 100,000/µL.***  
• Resume niraparib at a reduced dose per Table 4. 
Neutrophils < 1,000/ µL or Withhold niraparib for a maximum of 28 days and monitor 
UF-STO-ETI-001  14 February 2022 
42 of 92  
       CONFIDENTIAL   Version 2. 2   
*Dose reduction table to be followed regardless of timing of hematological toxicity  
**If MDS or AML is confirmed, discontinue niraparib.  
*** Discontinue niraparib if the platelet count, neutrophils and/or hemoglobin have not 
returned to acceptable levels within 28 days of the dose interruption period, or if the subject 
has already undergone dose reduction to 100 mg once daily.** * 
 
If a dose modification is required at any point on study due to hematologic toxicity, to ensure 
safety of the new dose, weekly blood draws for CBC will be required for an additional four weeks 
after the AE has been resolved to the specified levels, after which monitoring every four weeks 
may resume. If the hematologic toxicity has not recovered to the specified levels within four 
weeks (28 days) of the dose  hold  and/or the subject has already undergone a maximum of two 
dose reductions (to a minimum dose of 100 mg daily) , then the subject will permanently 
discontinue treatment with niraparib.  
 
Any subject requiring transfusion of platelets or red blood cells must undergo a dose reduction 
upon recovery if study treatment is resumed. Growth factors are allowed, but do not negate the 
requirement for dose reductions.  Continuation of growth factors for all subsequent cycles is 
allowed b ut at the discretion of the treating physician.  
 
The subject must be referred to a hematologist for further evaluation (1) if frequent transfusions 
are required or (2) if the treatment -related hematologic toxicities have not recovered to CTCAE 
Grade 1 or l ess after 4 weeks.  
 
For surgery while on treatment, up to 28 days of study treatment interruption is allowed. Once 
the dose of study treatment has been reduced, any re -escalation must be discussed with the 
study PI.  
All dose interruptions and reductions (i ncluding any missed doses), and the reasons for the Hemoglobin < 8 g/dL  
 
 blood counts weekly until neutrophil counts return to ≥ 
1,500/µL or hemoglobin returns to ≥ 9 g/dL***.  
Resume niraparib at a reduced dose per Table 4 
Hematologic adverse reaction 
requiring transfusion  For subjects with platelet count ≤ 10,000/µL, platelet 
transfusion should be considered. If there are other risk 
factors such as co - administration of anticoagulation or 
antiplatelet drugs, consider interrupting these drugs and/or 
transfusion at a higher platelet count.  
Resume niraparib at a reduced dose.  
Confirmed diagnosis of MDS* 
or AML†  Permanently discontinue niraparib.  
*MDS = myelodysplastic syndrome  
†AML = acute myeloid leukemia  
UF-STO-ETI-001  14 February 2022 
43 of 92  
       CONFIDENTIAL   Version 2. 2  reductions/interruptions, are to be documented in the subject’s study file.  
 
7.4 Supportive Care Guidelines  
 
Subjects should receive full supportive care, including transfusions of blood and blood products, 
antibiotics, antiemetics, antidiarrheals, analgesics, etc., when appropriate. Bisphosphonates or 
denosumab are allowed for subjects with bone metastases.  
 
7.5 Other Considerations  
 
Special consideration and caution should be given for subjects wi th previous radiation to the 
chest wall and/or lungs given report of pneumonitis with niraparib. This reported toxicity was 
thought to be secondary to radiation recall from previous radiation exposure to the lungs.  
 
8. TREATMENT DISCONTINUATION  
 
8.1 Removal of Subjects from  Study  
 
Subjects who discontinue participation in the clinical study on their own or subjects who are 
withdrawn by the investigator, for reasons other than completion of treatment, disease 
progression or toxicity, will be defined as  premature withdrawals.  
 
Subjects who are not initiated on study drug, but sign informed consent and undergo at least 
some of the screening procedures will be considered screening failures. A record of these 
subjects will be maintained by the study site.  
 
8.2 Criteria for Study Treatment Discontinuation  
 
A subject will be discontinued from protocol therapy under the following circumstances:  
• Any cancer therapy or new cancer -directed medication (except study drugs), 
administered from screening until thirty da ys following EOT.  
• Any adverse event which, in the Investigator’s opinion, requires termination of the study 
medication.  
• Disease progression, unless at the discretion of the principal investigator (in 
collaboration with any co -sponsors or collaborators) con tinued treatment with study 
drug is appropriate.  
• Substantial non -compliance with the requirements of the study.  
• The subject  presents with a beta -HCG test consistent with pregnancy. Pregnancy will be 
reported along the same timelines as a serious adverse event.  
• The subject  uses illicit drugs or other substances that may, in the opinion of the 
Investigator, have a reasonable cha nce of contributing to toxicity or otherwise 
UF-STO-ETI-001  14 February 2022 
44 of 92  
       CONFIDENTIAL   Version 2. 2  interfering with results.  
• The development of a second malignancy that requires treatment, which would 
interfere with this study.  
• The subject  is lost to follow -up. 
• Interruption in study drugs administration for g reater than twenty -eight days (see Dose 
Modification section).  
• Development of an intercurrent illness or situation which would, in the judgment of the 
investigator, affect assessments of clinical status and study endpoints to a significant 
degree.  
• Subject desire to discontinue therapy.  
 
The Investigator will make every reasonable effort to keep each subject  in the study unless it is 
in the subject’s best interests to discontinue participation. If a subject is removed from the study 
or declines further participation, all EOT evaluations should be performed if the subject  is willing 
and able to be assessed. A description of the reason(s) for withdrawal from the study must be 
recorded on the case report form (CRF). The Investigator should also ensure that all subjects are 
followed up for survival status after the Final Visit.  
 
Relevant visit data should be enter ed on the CRF and any unused study medication will be 
accounted for and returned for all subject s participating in the study, even for a brief period of 
time. Subjects who discontinue following entry will have relevant information completed and 
recorded on  the CRF. All subjects who discontinue because of adverse events or clinically 
significant laboratory abnormalities should be followed up until they recover or stabilize, and the 
subsequent outcome will be recorded. If any subject should die during the tri al or within 30 days 
of stopping study treatment, the Investigator will inform the UF Health Data Integrity and Safety 
Committee and the UF IRB as outlined in Section 11.4.  
 
8.3 Replacement of Subjects  
 
Subjects who do not receive any doses of study drug w ill be replaced. Subjects who receive any 
dose of study drug will contribute to safety and toxicity data, but will be replaced if they cannot 
provide response assessment due to study  discontinuation for  reasons other than disease 
progression  or toxicity.  
 
9. BIOLOGICAL SPECIMENS AND CORRELATIVES  
 
9.1 Source of Specimens  
 
Blood, serum, and plasma will be collected at different time points for study evaluations. All 
specimens collected as part of this study will be labeled with a study -specific ID number dist inct 
from their personal information. A master code key that links specimen ID with subject  identifiers 
UF-STO-ETI-001  14 February 2022 
45 of 92  
       CONFIDENTIAL   Version 2. 2  will be maintained in a restricted section of OnCore available only to the PI or approved study 
team delegates. A core needle (or excisional) biopsy mus t have been obtained within 3 years of 
study enrollment. If a new biopsy is obtained for diagnostic reasons, the biopsy must be 
performed from a tumor site that  is not the only site of measurable disease. For subjects with 
only one site of measurable disea se, biopsies from that site will be allowed if CT imaging 
performed after biopsy still shows measurable disease and/or the biopsy is not expected to 
impact the measurability of the lesion.  Discussion with the PI prior to biopsy is recommended.  
 
9.2 Tumor Analysis and Molecular Profiling  
 
For tumor analysis, a tumor block is preferred. As a substitute, 12 unstained slides are required. 
It is preferred that normal and tumor tissue be represented on the slide. This will be obtained for 
all archive tissue pre-treatment as well as any subject undergoing optional biopsy at end of 
treatment.  
 
9.3 Next Generation Sequencing  
 
Next Generation Sequencing (NGS) results are not required for enrollment in cohort A. If they are 
available from a CLIA -approved lab, resu lts will be recorded in the CRF. Histologic tumor type will 
take priority over molecular profile if a conflict arises between potential cohort assignments.  
 
For cohort B, subject  enrollment will be histology agnostic, but based on the presence of somatic 
molecular abnormalities involving any component of the DNA damage repair pathway, including: 
BAP1, PALB2, ATM, ATR, RAD51, RAD54, XRCC, ERCC, BLM, BARD, FANCD2, PTEN,  IDH1/IDH2 or 
BACH. NGS results will be permitted from any clinical or commercial vendor so  long as the assay 
is from a CLIA certified lab. Variants of unknown significance (VUS) are allowable for enrollment. 
Mutations involving BRCA (1 or 2) are NOT allowed on this study. A histology of prostate cancer 
is NOT allowed on this study.  
 
9.4 Correla tive Studies  
 
The following table represents some of the proposed correlative analyses associated with this 
trial. Collection of biospecimens will allow these and/or other analyses to take place in a pre - 
planned, but post -hoc manner. Alternative sources o f funding will be leveraged to perform these 
correlative analyses. Additional testing and hypothesis generating studies may be undertaken at 
the discretion of the study team. HRD assay will be chosen at the end of study enrollment but 
will be a commercial CLIA approved test (e.g., Myriad myChoice®). Only genetic tests that are 
obtain by the treating physician as part of routine clinical care will be disclosed to the subject  by 
the treating physician. No genetic test results from the correlative analyses in this study will be 
disclosed. Exploratory assessment of mutations may involve both somatic (tumor) and germline 
(blood) analyses.  
UF-STO-ETI-001  14 February 2022 
46 of 92  
       CONFIDENTIAL   Version 2. 2   
Table 7: Correlative Assessments by Cohort  
 
Cohort A Only  Both Cohorts  Cohort B Only  
BAP1 IHC on tumor tissue  
BAP1 gene sequencing  
Assessment of additional 
mutations of the DNA DSB 
repair pathway via NGS that 
enhance or impede BAP1 as 
a predictor of PARPi activity.  Exploring alternative biomarkers that 
could predict response (i. e. 
homologous  recombination deficiency 
score) to PARP inhibition  BAP1 gene 
sequencing  
Exploratory assessment of circulating 
biomarkers of response (i.e. peripheral 
immunome, circulating tumor DNA)  
Tumor biopsy upon progression in 
subset of subject s to explore 
mechanisms of resistance to PARP 
inhibitio n including, but not limited to, 
BRCA overexpression and/or alternate 
activation of HR pathway  Cross -referencing 
mutations with known 
databases (retrospectively) 
to evaluate whether 
germline or somatic in 
origin  
Determination of 
previously undocumented  
VUS as predictors of PARPi 
activity  
 
9.2 Preparation, Shipment and Storage of Specimens  
Refer to the Study Procedure Manual for collection, processing and shipping instructions for all 
tissue and blood specimens.  
 
Formalin -fixed paraffin -embedded tumor tissue must be submitted prior to start of study drug. 
A tissue block or minimum of 12 slides is required. Tissue must have been obtained via routine 
care within 3 years of study enrollment or new specimens are required to be collected. Blood 
collected will be processed to isolate DNA and RNA for future potential genetic analyses.  
 
All blood and tissue samples will be labeled with the subject’s unique study number and 
physically store d. During the life of the stu dy, these biospecimens remain available only to the 
study team and only those exploratory analyses listed in Table 7 will be considered, unless added 
through a protocol amendment. For analyses that require research collaborations outside of UF, 
only de -identified specimens will be shared. Samples will be stored for the life of the study and 
will then be destroyed or transferred to  a UF CTSI Biospecimen  bank  for general research use  if 
subjects agree to enroll in the separate banking study .  
 
At study enroll ment, all subjects will be given the option to provide permission for their blood 
and tumor tissue samples to be collected and stored for long -term use (i.e., beyond the life of 
this study). Thus, future research on remaining biospecimens after the study -specific analyses 
have been completed can only be considered by subjects providing their additional consent  on 
UF-STO-ETI-001  14 February 2022 
47 of 92  
       CONFIDENTIAL   Version 2. 2  an IRB- approved study consent form  for optional biobanking.   Future specific use of those 
biomaterials will require secondary IRB approval. At th e closure of this treatment trial, any 
biospecimens remaining from subjects who have provided consent for long -term storage/use will 
be destroyed or transferred to the UF CTSI Bio bank . For subjects who consent to the treatment 
study, but decline secondary long -term storage, their biomaterials will be destroyed at the 
completion of the treatment trial and will not be transferred.  
 
Subjects may be given the option to undergo a tumor biopsy at the end of their participation as 
well.  
 
10. STUDY DRUG INFORMATION  
Study Drug Name : 
Niraparib (formerly known as MK -4827, TESARO, Inc.)  
 
Identification : 
Chemical Name: [3S]-3- [4-31 phenyl] piperidine  [tosylate monohydrate salt].  
Chemical Structure:  
Molecular Formula:  C26H30N4O5S  
Molecular Weight:  510.617 Daltons  
 
Physical Description:  
Niraparib drug substance is a crystalline tosylate monohydrate salt. This salt form is non - 
hydroscopic and is off -white to pale brown in color. Niraparib has an aqueous solubility 
of 0.80 mg/mL.  
 
10.1  Administration  
Niraparib (100 mg) tablets will be administered orally QD continuously. Niraparib will be 
administered as a flat -fixed dose (100 mg, 200 mg or 300 mg daily), and not by body weight or 
body surface area. Niraparib should be swallowed whole without chewing. Food does not 

UF-STO-ETI-001  14 February 2022 
48 of 92  
       CONFIDENTIAL   Version 2. 2  significantly affect the absorption of niraparib; therefore, niraparib may be taken without regard 
to meals. Subject s should take doses at approximately the same times each day. Bedtime 
administration may be a potential method for managing na usea.  
 
Niraparib treatment should be continued until disease progression.  
 
If a subject misses a dose of niraparib, they should take their next dose at its regularly scheduled 
time.  
 
Subjects must be instructed to return unused study drugs to the site at d iscontinuation or 
completion of treatment. The site personnel must ensure that the appropriate dose of each study 
drug is administered and that the drug accountability is performed.  
 
10.2  Packaging  
Packaging: Niraparib drug product is packaged in high -density polyethylene (HDPE) bottles with 
child -resistant plastic closures. The label test of the study treatment will comply with Good 
Manufacturing Practice and national legislation to meet the requirements of the participating 
countries.  
 
All study treatment supplies must be stored in accordance with the storage and handling manual 
instructions and package labeling. Until dispensed to subjects, the study treatment will be stored 
in a securely locked area, accessible to authorized staff only.  
 
10.3  Drug Supply  
 
The University of Florida will distribute study drug to affiliate site(s). The initial study drug 
shipment will be shipped after site activation (i.e., all required regulatory documentation has 
been received by the Sponsor and a contract has b een executed).  
 
Subsequent study drug shipments will be made after site request for resupply.  
 
10.4  Storage, Handling and Dispensing  
All investigational study drug supplies must be store at room temperature and in accordance with 
the Sponsor’s instructions . Refer to the storage and handling manual for further details.  
 
10.5  Contraindications  
Treatment with niraparib is contraindicated in individuals with hypersensitivity to any 
component of the drug, or as indicated within the study protocol.  
Subjects and t heir partners must be completely informed of the risks of pregnancy. Niraparib 
UF-STO-ETI-001  14 February 2022 
49 of 92  
       CONFIDENTIAL   Version 2. 2  may have adverse effects on a fetus in utero. Furthermore, it is not known if niraparib has 
transient adverse effects on the composition of sperm.  
 
Subjects may not receive nira parib in the study if they are pregnant, planning to become 
pregnant, or nursing a child. Subjects must agree to use contraception for the entire course of 
the study and must inform the investigator immediately if they or their partner become pregnant. 
If a pregnancy occurs, treatment with niraparib will be stopped immediately and the subject will 
be followed until the end of pregnancy.  
 
10.6 Clinically Reported Adverse Reactions  
 
The following adverse reactions (all CTCAE grades) have been reported in ≥20%  of subject s who 
received niraparib: anemia, thrombocytopenia, nausea, constipation, vomiting, fatigue, platelet 
count decreased, decreased appetite, headache, and insomnia. The median exposure to 
niraparib in all of these subject s was 250 days.  
 
The following adverse reactions and laboratory abnormalities have been identified in ≥10 to 20% 
of the 367 subject s receiving niraparib: neutropenia, palpitations, asthenia, neutrophil count 
decreased, dizziness, dysgeusia, dyspnea, cough and hypertension.  
 
The following adverse reactions and laboratory abnormalities have been identified in ≥1 to <10% 
of the 367 subject s receiving niraparib: tachycardia, dry mouth, mucosal inflammation, white 
blood cell count decreased, aspartate aminotransferase increased,  alanine aminotransferase 
increased, and photosensitivity reaction.  
 
Hypertension, including hypertensive crisis, has been reported with the use of niraparib.  
Pre-existing hypertension should be adequately controlled before starting niraparib treatment. 
Blood pressure and heart rate should be monitored at least weekly for the first 2 months, then 
monthly for the first year and periodically thereafter during treatment with niraparib.   
Hypertension should be medically managed with antihypertensive medicinal p roducts as  
well as adjustment of the niraparib dose, if necessary. In the clinical program, blood  
pressure measurements were obtained on Day 1 of each 28 day cycle while the patient  
remained on niraparib. In most cases, hypertension was controlled adequate ly using  
standard antihypertensive treatment with or without niraparib dose adjustment. Niraparib  
should be discontinued in case of hypertensive crisis or if medically significant  hypertension 
cannot be adequately controlled with antihypertensive therapy.  
 
Posterior Reversible Encephalopathy Syndrome (PRES):  There have been rare reports of 
niraparib -treated patients developing signs and symptoms  that are consistent with Posterior 
Reversible Encephalopathy Syndrome (PRES).  PRES is  a rare neurologic disorder that can 
present with the following signs and symptoms  including seizures, headache, altered mental 
UF-STO-ETI-001  14 February 2022 
50 of 92  
       CONFIDENTIAL   Version 2. 2  status, visual disturbance, or cortical  blindness, with or without associated hypertension. A 
diagnosis of PRES requires  confirmation by brain imaging, pref erably magnetic resonance 
imaging.   In patients developing PRES, treatment of specific symptoms including control of 
hypertension is  recommended, along with discontinuation of niraparib. The safety of 
reinitiating  niraparib therapy in patients previously e xperiencing PRES is not known.  
 
11. ADVERSE EVENTS  
 
11.1  Definition  
The term “adverse event” (AE) includes any sign, symptom, syndrome, or illness that appears or 
worsens in a subject during the period of observation in the clinical study and that may impair 
the wellbeing of the subject. The term also covers laboratory findings or results of other 
diagnostic procedures that are considered to be clinically significant (e.g., that requires 
unscheduled diagnostic procedures or treatment measures, or result  in withdrawal from the 
study). An AE is therefore any unfavorable and unintended symptom or disease temporally 
associated with the administration of an investigational product, whether or not related to that 
investigational product.  
The adverse event may be: 
• A new illness/condition;  
• Worsening of a sign or symptom of a concomitant illness/condition;  
• An effect of the study drug; or  
• A combination of 2 or more of these factors.  
 
No causal relationship with the study drug or with the clinical study itself is implied by the use 
of the term “adverse event.”  
 
The Investigator will probe, via discussion with the subject, for the occurrence of AEs during each 
subject visit and record the information in the site’s source documents. AEs will be recorded in 
the subjec t CRF. AEs will be described by duration (start and stop dates and times), severity, 
outcome, treatment and relation to study drug, or if unrelated, the cause.  
 
Surgical procedures themselves are not adverse events; they are therapeutic measures for 
condit ions that require surgery. The condition(s) for which the surgery is required may be an 
adverse event. Planned surgical measures permitted by the clinical study protocol and the 
condition(s) leading to these measures are not adverse events.  
 
When a clear d iagnosis is available that explains the abnormal objective findings, this diagnosis 
will be recorded as an adverse event and not the abnormal objective findings (e.g., viral hepatitis 
will be recorded as the adverse event and not the transaminase elevation ). If a definitive 
diagnosis is not available, then the sign(s) (e.g., clinically significant elevation of transaminase 
UF-STO-ETI-001  14 February 2022 
51 of 92  
       CONFIDENTIAL   Version 2. 2  levels) or symptom(s) (e.g., abdominal pain) will be recorded as the adverse event.  
 
Adverse events fall into the categories “serious” a nd “non -serious.”  
 
11.1.1  Serious Adverse Event  
A serious adverse event is one that at any dose of the study drug or at any time during the 
period of observation:  
• Results in death , unless the death is due to expected disease progression as outlined in 
section 11.2  
• Is life -threatening (defined as an event in which the subject was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe)  
• Requires inpatient hospitalization or c auses prolongation of existing hospitalization (see 
note below for exceptions)  
• Results in persistent or significant disability/incapacity  
• Is a congenital anomaly/birth defect  
 
• Is an important medical event, defined as a medical event that may not be immediately 
life-threatening or result in death or hospitalization but, based on appropriate medical 
and scientific judgment, may jeopardize the subject or may require intervention (e.g., 
medical, surgical) to prevent one of the other serious outcomes list ed above. Examples 
of such events include but are not limited to intensive treatment in an emergency 
department or at home for allergic bronchospasm; blood dyscrasias or convulsions that 
do not result in hospitalization. “Medically important” should be mar ked only if no other 
serious criteria are met.  
 
An “unexpected SAE” is any SAE for which the nature, specificity or severity is not consistent 
with the currently known adverse event profile of the investigational agent(s).  
 
NOTE: The following hospitalizat ions are not considered SAEs in UFHCC clinical studies:  
 
A visit to the emergency room or other hospital department lasting less than 24 hours that does 
not result in admission (unless considered an  “important medical event” or a life-threatening 
event) : 
• elective surgery planned before signing consent  
• admissions as per protocol for a planned medical/surgical procedure  
• routine health assessment requiring admission for baseline/trending of health status 
(e.g., routine colonoscopy)  
• medical/surgical admission for purpose other than remedying ill health state that was 
planned before study entry. Appropriate documentation is required in these cases.  
UF-STO-ETI-001  14 February 2022 
52 of 92  
       CONFIDENTIAL   Version 2. 2  • admission encountered for another life circumstance that carries no bearing on health 
status and requires no medica l/surgical intervention (e.g., lack of housing, economic 
inadequacy, caregiver respite, family circumstances, administrative).  
 
11.1.2  Clarification of the difference in meaning between “severe” and “serious”  
The term “severe” is often used to describe the  intensity (severity) of a specific event (as in mild, 
moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor 
medical significance (such as severe headache). Any grade ≥ 3 adverse events  per CTCAE is 
generally con sidered severe AE. This is not the same as “serious,” which is based on the outcome 
or action criteria usually associated with events that pose a threat to life or functioning. 
Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.  
 
11.1.3  Non-Serious Adverse Event  
A non -serious adverse event is any adverse event not meeting any of the serious adverse event 
criteria.  
 
11.1.4  Period of Observation  
Following the subject’s written consent to participate in the study, all SA Es and AESIs must be 
collected, including those thought to be associated with protocol -specified procedures. 
Collection of all SAEs and AESIs must continue for 90 days after the last administration of the 
investigational product (or to a minimum of 30 days  post -treatment if the subject starts alternate 
anticancer therapy). If applicable, SAEs must be collected that relate to any later protocol - 
specified procedure (e.g., a n optional  follow -up tumor biopsy). The investigator should notify the 
DISC of any SAE  occurring after this time period that is believed to be related to the 
investigational product or protocol -specified procedure.  
 
The investigator will begin collecting non -serious adverse event (NSAE) information from the 
time of the subject’s written consent and must continue until 30 days after the last administration 
of the investigational product. This NSAE information should also be collected from the start of a 
placebo lead -in period or other observational period intended to establish a baseline s tatus for 
the subjects. Treated subjects, including those who were prematurely discontinued from the 
study, will be followed for any adverse events that occur during the study until thirty days 
following the last dose of study treatment (i.e., the Follow -up Visit). If at any time after the study 
is completed, an Investigator becomes aware of an SAE that is considered related to the 
investigational product, the Investigator should report the SAE to the Sponsor's  
Pharmacovigilance Department within 24 hours o f becoming aware of the SAE  
 
Disease progression is an efficacy criterion and is therefore not considered an AE or SAE (even if 
UF-STO-ETI-001  14 February 2022 
53 of 92  
       CONFIDENTIAL   Version 2. 2  fatal). Disease progression should be documented but not reported as an SAE. If AEs/SAEs occur 
in relation to disease progression that are not consistent with the natural progression of the 
subject ’s disease, these AEs/SAEs must be reported per  AE/SAE repo rting requirements.  
 
11.2  Documenting and Reporting of Adverse Events by Investigator  
All adverse events must be fully recorded in the subject’s case record form.  
 
Documentation must be supported by an entry in the subject’s file. A laboratory test abnorma lity 
considered clinically relevant, e.g., causing the subject to withdraw from the study, requiring 
treatment or causing apparent clinical manifestations, or judged relevant by the investigator, 
should be reported as an adverse event. Each event should be  described in detail along with start 
and stop dates, severity, relationship to investigational product, action taken and outcome.  
 
Every attempt should be made to describe the adverse event in terms of a diagnosis that 
encompasses the component signs and symptoms. If only nonspecific signs or symptoms are 
present, then these should be recorded as separate diagnoses on the pages of the case report 
form.  
 
All subjects who have adverse events, whether considered associated with the use of study drug 
or not, m ust be monitored to determine the outcome. The clinical course of the adverse event 
will be followed according to accepted standards of medical practice, even after the end of the 
period of observation, until a satisfactory explanation is found or the Prin cipal Investigator 
considers it medically justifiable to terminate follow -up. Should the adverse event result in death, 
a full pathologist’s report should be supplied, if possible.  
 
Assessment of Causal Relationship of Study Drug  
 
The Investigator will pro vide an assessment of the potential causal relationship between adverse 
events and study medication by determining whether or not there is a reasonable possibility that 
the event was caused by the study medication. The relationship or association of the ad verse 
event to the study medication will be characterized as not related, probably not related, possibly 
related, probably related, or related:  
• Not Related : There is not a temporal relationship to the study drug administration or 
the adverse event is clear ly due only to the progression of the underlying disease state, 
intercurrent illness, concomitant medication, concurrent therapy or other known cause.  
• Probably Not Related : There is little or no chance that the study drug administration 
caused the adverse event; the event is most likely due to another competing cause, 
including intercurrent illness, progression or expression of the disease state, or a 
reaction to a concomitant medication or concurrent therapy appearing to explain the 
reported adverse event.  
UF-STO-ETI-001  14 February 2022 
54 of 92  
       CONFIDENTIAL   Version 2. 2  • Possibly Related:  The association of the adverse event with the study drug 
administration is unknown; however, the adverse event is not reasonably attributed to 
any other condition.  
• Probably Related:  When a reasonable temporal relationship exists between the adverse 
event and the study drug administration; significant symptoms abate upon 
discontinuation of the study drug and there is a reasonable explanation based on known 
characteristics of the study drug and there is no clear association with preexisting  
disease or therapy, intercurrent illness, concurrent therapy or other factor(s).  
• Related:  When the adverse event is a known side effect of the study drug or there is a 
temporal relationship to the administration of the study drug; or the adverse event 
reappears upon re - administration of the study drug (rechallenge); or the significant 
symptoms of the adverse event abate upon discontinuation of the study drug 
(dechallenge).  
 
 
 
 
 
 
NOTE: For causal relationships needing to be reported to external entities which require a 
Related/Not Related or Yes/No data format, the categorization of study drug attribution will be 
as follows:  
• Yes, or Related = Related, Probably Related, and Possibly Related  
• No, or Not Related = Not Related and Probably Not Related  
 
11.2.1  Intensity of Adverse Events  
The intensity of adverse changes in physical signs or symptoms will be graded according to the 
CTCAE version 4.03 . For all other adverse events not described in the CTCAE, the intensity will be 
assessed by the Investigator using  the following categories:  
• Mild (Grade 1)  – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required.  
• Moderate (Grade 2) – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medica l intervention/therapy required.  
• Severe (Grade 3)  – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible.  
• Life-threatening (Grade 4)  – extreme limitation in activity, significan t assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable.  
• Death (Grade 5)  – the event resulted in death.  
 
UF-STO-ETI-001  14 February 2022 
55 of 92  
       CONFIDENTIAL   Version 2. 2  11.2.2  Action Taken with Study Drug  
The action the Investigator took with study drug as a re sult of the event should be recorded as 
one of the following:  
• None  – No action was taken with regard to the study drug as a result of the adverse 
event.  
• Interrupted  – Study drug was stopped due to the adverse event, but was later resumed 
at the same dose.  
• Dose decreased  – The dose of study drug was decreased as a result of the adverse 
event.  
• Permanently discontinued – The subject was withdrawn from the study due to the 
adverse event.  
 
Only one item should be chosen. If multiple actions apply, the following “worst case” scenario 
hierarchy should be used to determine the preferred entry:  
Discontinued > dose decreased > therapy interrupted.  
 
11.2.3  Definition of Outcome  
The outcome of the AE should be recorded as one of the following:  
• Resolved without sequelae – The subject fully recovered from the adverse event with no 
observable residual effects.  
• Resolved with sequelae – The subject recovered from the adverse event with observable 
residual effects.  
• Not resolved – The adverse event was present at the time of la st observation.  
• Death – The subject died as a result of the adverse event.  
 
11.3  Immediately Reportable Events  
 
11.3.1  Serious Adverse Events  
Serious adverse events (SAE's) and adverse events of special interest (AESIs) must be emailed  to 
the UFHCC DISC Safety Team within 5 days of discovery of the event and the UFHCC Project 
Management Office ( pmo@cancer.ufl.edu ) within 24 hours  of discovery of the event. The original 
copies of any reports and related email correspondence must be kept within the study files  at 
the study site. The site investigator is responsible for informing the UF IRB and/or the Regulatory 
Authority of the SAE as per local requirements.  
 
Follow -up information will be emailed or faxed to the UFHCC Project Management Office 
(pmo@cancer.ufl.edu ), stating  that this is a follow -up to the previously reported SAE and giving 
UF-STO-ETI-001  14 February 2022 
56 of 92  
       CONFIDENTIAL   Version 2. 2  the date of the original report . Each re -occurrence, complication, or progression of the original 
event should be re ported as a follow -up to that event regardless of when it occurs. The follow -
up information should describe whether the event has resolved or continues, if and how it was 
treated \, and whether the participant continued or wi thdrew from study participation  
 
Institution SAE and Pregnancy Reporting Information  
SAE reports must be emailed to the DISC Coordinator, or assigned  designee , and the 
UFHCC Project Management Office at: 
Email: UFHCC -DSMB@ahc.ufl.edu  and pmo@cancer.ufl.edu  
 
11.3.2  Other Events Requiring Immediate Reporting  
All pregnancies, regardless of outcome, must be reported to the UFHCC DISC, including 
pregnancies that occur in the female partner of a male study subject. All pregnancies must be 
followed to outcome even if the subject  was withdrawn from the clinical stud y or the clinical 
study was completed. TESARO /GSK will be informed of all pregnancy outcomes as the event is 
made aware to the UF Health Cancer Center. Any pregnancies of female study subject s and 
partners of male study subject s that occur within 180 days following the last dose of study 
treatment must be reported.  
 
The Coordinating Center has the responsibility to monitor the outcome of all pregnancies 
reported during the Investigator Sponsored Trial.   The Coordinating Center must report all 
pregnancies associated with TESARO /GSK  product including follow up outcomes to TESARO /GSK  
within 24 hours of awareness.  
 
Each pregnancy must be reported on an Initial Pregnancy Report Form within 24 hours of 
becoming aware of the pregnancy. Pregnancy is not an AE, and  therefore does not need to be 
reported as an AE unless there is a suspicion that the study drug may have interfered with the 
effectiveness of a contraceptive medication.  
 
An elective abortion without complications should not be regarded as an AE, however,  it should 
be reported as the outcome to the pregnancy on the Pregnancy Outcome Report Form.  
 
Therapeutic abortions should be reported as a treatment procedure; the reason for the 
therapeutic abortion should be reported on the Pregnancy Outcome Report Form  and as an AE. 
Hospitalization for normal delivery of a healthy newborn should not be considered an SAE.  
 
Any SAE that occurs during pregnancy must be recorded on the Pregnancy Outcome Report Form, 
reported as an SAE (e.g., maternal serious complications, therapeutic abortion, ectopic 
UF-STO-ETI-001  14 February 2022 
57 of 92  
       CONFIDENTIAL   Version 2. 2  pregnancy, stillbirth, neonatal d eath, congenital anomaly, birth defect) and reported to the 
Coordinating Center and TESARO /GSK  within 24 hours. Hospitalization for normal delivery of a 
healthy newborn should not be considered an SAE.  
 
Special Situations: Abuse, Misuse, Medication Errors, Overdose, and Accidental or Occupational 
Exposure  
Abuse: is the persistent or sporadic, inten tional excessive use of the study treatment which is 
accompanied by harmful physical or psychological effects.  
• Misuse : medicinal product is intentionally and inappropriately used not in accordance 
with the authorized/approved product information.  
• Medicatio n error : is any preventable incident that may cause or lead to inappropriate 
study treatment use or subject  harm while the study treatment is in the control of the 
health care professionals or subject s. Such incident may be due to health care 
professional practice, product labeling, packaging and preparation, procedures for 
administration, and systems, including the following: prescribing, order communication, 
nomenclature, compounding, dispensing, distribution, administration, education, 
monitoring, and us e. 
 
• Overdose : is a deliberate or accidental administration of study treatment to a study 
subject , at a dose greater than that which was assigned to that subject  per the study 
protocol and under the direction of the Investigator. If an overdose with a TESAR O/GSK  
product, the Coordinating Center and TESARO /GSK  should be notified immediately, and 
the subject  should be observed closely for AEs. Associated AEs should be treated and 
monitored by the Investigator. The dosage of study drug administered, any associa ted 
AEs, and/or treatment provided to the subject  because of the overdose, should be 
reported.  
• Accidental /Occupational exposure : is the unintentional exposure to a study treatment 
as a result of one’s professional or non -professional occupation, or accide ntal exposure 
to a non -professional to whom exposure was not intended (i.e., study product given to 
wrong subject ). 
 
Reporting Special Situations: All occurrences of abuse, misuse, medication error, overdose, and 
accidental or occupational exposure associa ted with a TESARO /GSK  product must be reported on 
a Special Situations Report Form to the Coordinating Center and to TESARO /GSK  within 5 
business days of awareness regardless of whether or not an AE or SAE has occurred. If the abuse, 
misuse, medication err or, overdose, or accidental / occupational exposure is associated with an 
AE, an SAE Report Form must also be submitted to the Coordinating Center and to TESARO /GSK  
within 24 hours of awareness.  
 
Although overdose (dose variance of >33%) and cancer are not  always serious by regulatory 
definition, these events should also be reported to the DISC in an expedited manner. In case the 
UF-STO-ETI-001  14 February 2022 
58 of 92  
       CONFIDENTIAL   Version 2. 2  overdose did not result in any adverse event, the Investigator should report this as “overdose, 
no adverse event” on the SAE form  and provide the intended amount, as well as the actual 
amount, of drug administered. In the event of overdose or exaggerated response, appropriate 
supportive measures should be employed. Actual treatment should depend on the severity of 
the clinical situa tion and the judgment and experience of the treating physician.  
 
Overdoses should be documented and reported per the SAE reporting guidelines in section  
above.  
 
11.4  Suspected Unexpected Serious Adverse Reactions (SUSARs)  
For any AE that is serious, associated with the use of the study treatment, and unexpected 
(defined as any term not listed in the expectedness section of the current Investigator’s Brochure 
or current prescribing information) additional reporting requirements are described below. 
These types of reports are referred to as (SUSARs).  
 
For interventional clinical trials, if the SUSAR is fatal or life -threatening, associated with the use 
of the study treatment, and unexpected, the Sponsor will report to Regulatory Authorities and 
Independe nt Ethics Committees (IECs) within 7 calendar days after the Investigator learns of the 
event. Additional follow -up (cause of death, autopsy report, and hospital report) information 
should be reported within an additional 8 days (15 days total).  
 
For all o ther SUSARs, the Sponsor will report to Regulatory Authorities and IECs within 15 
calendar days after the Sponsor learns of the event.  
 
The Sponsor will also provide annual safety updates to the Regulatory Authorities and IECs 
responsible for the study. Th ese updates will include information on SUSARs and other relevant 
safety findings.  
 
11.4.1  SUSAR Distribution  
A central contact at the Coordinating Center is responsible for the review and distribution of any 
SUSARs received from TESARO /GSK  for TESARO /GSK ’s Investigational Product for the duration of 
this study.  
 
Adverse Events of Special Interest  
 
Selected nonserious AEs and SAEs are also known as Adverse Events of Special Interest (AESI) and 
must be reported within 24 hours of awareness of the event to th e Coordinating Center and to 
TESARO /GSK  regardless of causality assessment to study drug.  
 
UF-STO-ETI-001  14 February 2022 
59 of 92  
       CONFIDENTIAL   Version 2. 2  11.4.2  Adverse Events of Special Interest (AESI)s  
Adverse Events of Special Interest (A ESI)s for this trial are defined as:  
• Myelodysplastic Syndromes (MDS) and Acute  Myeloid Leukemia (AML)  
• Secondary cancers (new malignancies [other than MDS or AML])  
• Pneumonitis  
• Embryo -fetal toxicity  
 
AESIs should be reported on SAE Report Forms whether serious or not, as follows:  
• MDS and AML along with other secondary cancers should be reported to the 
Coordinating Center and to TESARO /GSK  upon awareness for any subject  who has 
received niraparib (regardless of the timeframe since the last dose).  
• Pneumonitis should be reported to the Coordinating Center and to TESARO through 90 
days af ter the last dose of niraparib.  
• Embryo -fetal toxicity should be reported as outlined in the Pregnancy reporting section.  
 
For any suspected MDS/AML case reported while a subject is receiving treatment or being 
followed for post -treatment assessments, bone marrow aspirate and biopsy testing must be 
completed by a local hematologist. A whole blood sample will also be collected for cytogenetic 
analysis (mutations of select myeloid -associated genes). Testing completed as part of standard 
of care is sufficient a s long as the methods are acceptable to the Sponsor's Medical Monitor. The 
study site must receive a copy of the hematologist’s report of aspirate/biopsy findings (which 
must include a classification according to World Health Organization criteria) and oth er sample 
testing reports related to MDS/AML. The site must keep a copy of the report  with the subject’s 
study file.  
 
11.4.3  Sponsor Reporting  
Sponsor will forward any SAE, AESI, or pregnancy to  GSK within 24 hours of becoming aware of 
the event. The institution will forward both initial and follow -up versions of each report.  
 
The Sponsor must provide a causality assessment and must sign and date any SAE reports.  
 
If supporting documentation is included in the submission to  GSK(e.g., hospital reports,  
consultant reports, death certificates, autopsy reports, etc.), please redact any subject  identifiers 
(including Medical Record number).  
 
 GSKSAE, AESI, and Pregnancy Reporting Information  
 OAX37649@GSK.com  
UF-STO-ETI-001  14 February 2022 
60 of 92  
       CONFIDENTIAL   Version 2. 2   
On at least an annual basis, Sponsor will provide a copy of the safety reports submitted to 
applicable Regulatory Authorities or IECs. Annual reports should be provided to  GSK within 3 
business days of submission to the applicable regulatory body.  
 
11.4.4  Reporting Product Quality Complaints for Niraparib  
Any written, electronic or oral communication that alleges dissatisfaction related to 
manufactured clinical drug product with regards to its manufacturing, testing, labeling, 
packaging, or shipping, must be reported by the sponsor -investigator or qualified designee to 
TESARO (  tesaro.qa@gsk.com ) within 1 working day of first becoming aware of the possible 
defect. This report to TESARO may also be made by telephone to the designated TESARO 
representative (1 -844-4TESARO). The product and packaging components in question, if 
available, must be stored in a secure area under specified storage conditions until it is determined 
whether the product is required to be returned for investigation of the defect. If the product 
complaint is associated with an SAE, the SAE must be reported separately in accordance with the 
protocol, and the SAE report should mention the product quality complaint.  
11.4.5  IND Safety Reports Unrelated to this Trial  
IND safety reports not occurring on this trial but involving the study intervention (outside SAEs) 
received from outside sources will be forwarded to participating sites for submission to their 
Institutional Review Boards per their guide lines.  
 
12.0  STATISTICAL METHODS  
The secti ons below provide an overview of the statistical considerations and analyses.  
 
12.1  Sample Size Determination  
Cohort A :  Simon's optimal two-stage design will be used for Cohort A. The null hypothesis that 
the true objective response rate (ORR) is 10% . This is based upon prior evidence that the vast 
majority of tumors without DNA repair deficiencies are unaffected by the use of PARP inhibition. 
The null hypothesis will be tested against a one -sided alternative. In the first stage, 1 8 patients 
will be a ccrued. If there are 2 or fewer responses in these 1 8 patients, the study will be stopped. 
Otherwise, 1 7 additional patients will be accrued for a total of 35. The null hypothesis will be 
rejected if >= 7 responses are observed in 35 patients. This design yields a type I error rate of 
0.05 and power of 90% when the true ORR is 30%.  
 
Cohort B : The sample size  for Cohort B is based on a n estimated increase in the ORR  from 10% 
(H0) to 50% (H1) in this molecularly selected/enriched patient population . A sample size of  9 
patients achieves at least 90% power to detect a difference of 40% , using a one-sided exact test 
with a significance level of 0.05. Considering 20% dropout rate, we will accrual a total of 12 
UF-STO-ETI-001  14 February 2022 
61 of 92  
       CONFIDENTIAL   Version 2. 2  patients for Cohort B.  
 
Thus, a total sample size of 47 subject s is proposed  inclusive of both Cohorts A and B . 
 
Optional Cohort A Expansion : Given th e histologic heterogeneity of subjects in  Cohort A (all 
serving as means to enrich for BAP1 mutations), so as not to miss a legitimate signal of activity in 
a histology -specific manner, we will consider an option al cohort A expansion of any histology  that 
suggest s substantial activity. Thus, after completion and analysis of the primary endpoint in 
Cohort A , and independent of the final ORR for the entire cohort,  if the ORR is > 30% (H1) within 
any of the histology categories required for eligibility (i.e., mesothelioma), an expansion cohort 
of an additional 20 subject s of that specific histology will be considered, pending further 
discussion with the study team and procurement of funding. This can be performed for each of 
the four histologies defined in Cohort A , and about 20 to 80 additional subjects may be enrolled 
to up to four histology -specific expansion groups . This histology -specific expansion (20 minimum) 
provides > 80% power to assure  a degree of activity (one -sided alpha 0.05; Beta 0.10; ORR 10% 
(H0) to 30% (H1) ) suggested by the initial Cohort A analysis.  
 
12.2 Analysis of Primary Endpoint  
Objective response rate (ORR as determined by RECIST Version 1.1 criteria) of niraparib treated 
subject s in each cohort. The ORR is equal to the proportion of subject s achieving a best overall 
response of partial or complete  response (CR + PR), according to RECIST from the start of the 
treatment until disease progression/recurrence or 30 days after the end of treatment, whichever 
occurs first. Clinical benefit rate is equal to the objective RR plus the proportion of subject s 
attaining stable disease (CR + PR + SD ). The  number of subjects achieving a response will be 
divided by the total of subject s treated to yield the proportion responding. Exact confidence 
bounds (95% CI) will be calculated. The primary statistical analysis will use the modified Intention -
to-Treat (mITT) population consisting of subject s who are enrolled and received any dose of study 
medication. The mITT population will be included in summary tables of subject  demographics 
and disease characteristics, and in  analysis of efficacy. Statistical analyses will be conducted by 
the study biostatistician using SAS v9.1 (SAS Institute, Cary, NC).  
 
12.3  Analysis of Secondary Endpoints  
Secondary endpoints will be analyzed in a descriptive manner. The PFS rate at 3 and 6  months 
will be estimated by the Kaplan -Meier (KM) analysis along with median OS based on cohort 
assignment as well as molecular or histology category.  The PFS is defined as the duration of time 
from study entry to time of progression or death or the date  of last contact, whichever occurs 
first. OS is defined as the time from study entry to time of death or date of last contact. Subjects 
who did not progress  (death)  or are lost to follow -up will be censored at the day of their last 
objective tumor assessme nt. 
UF-STO-ETI-001  14 February 2022 
62 of 92  
       CONFIDENTIAL   Version 2. 2   
12.4  Analysis of Exploratory Endpoints  
Exploratory biomarkers will be analyzed post -hoc. Correlative analyses of response and outcomes 
relative to confirmation/mechanism of BAP1 loss, other DDR pathway dysfunction, histology and 
homologous recombination deficiency (HRD) status will be performed . HRD assay may be 
performed in conjunction with third parties to assess predictive response toniraparib treatment. 
Other analyses will be performed by investigators at the University of Florida. Descriptive 
statistics and any associated relationships with  clinical outcomes will be reported.  
 
12.5  Analysis of Safety Data  
The incidence, severity and reversibility of toxicities in subjects treated with niraparib will be 
performed on all subject s who receive any dose of study medication. Non -serious adverse ev ents 
that occur more than 30 days after the administration of the last dose of treatment will not be 
included. The safety and tolerability of treatment is determined by reported AEs, physical 
examinations, laboratory tests, and ECGs. AEs will be summarized  with the incidence and 
percentage of subject s with at least one occurrence of a preferred term (according to the most 
severe NCI -CTCAE Version 4.03  grade) will be included. The number of AEs reported will also be 
summarized. Causality (relationship to study drug) will be summarized separately. Duration of AE 
will be determined and included in listings along with action taken and outcome.  
 
Laboratory results will be classified according to NCI -CTCAE, Version 4.03 . Incidence of laboratory 
abnormalities will be summarized; laboratory results not corresponding to an NCI - CTCAE Version 
4.03  term will not be graded. Laboratory toxicity shifts from baseline to worst grade will also be 
provided. The results from physical examination and vital sign measurement will be tabulated. 
Descriptive statistics will be provided as appropriate.  
 
12.6  Interim Analysis  
The interim analysis will correspond directly with the Simon two -stage design, as described for 
Cohort A, in section 12.1. An analysis will be performed after the first 18 subjects are enrolled. 
At this time the safety and tolerability of the study drug will be assessed and, if deemed safe, 
enrollment will con tinue to 35 subjects if three or more subjects dem onstrate an objective 
response.  
 
13. DATA AND SAFETY MONITORING  
 
13.1  Data Integrity and Safety Committee  
This protocol will be reviewed and monitored by the University of Florida Health Cancer Center 
(UFHC C) DISC in accordance with their policies and procedures. They will review and monitor 
UF-STO-ETI-001  14 February 2022 
63 of 92  
       CONFIDENTIAL   Version 2. 2  study progress, toxicity, safety and other data from this trial. Questions about subject safety or 
protocol performance will be addressed with the sponsor -investigator, statistician and study 
team members. Should any major concerns arise; the DISC will offer recommendations regarding 
whether or not to suspend the trial.  
 
UFHCC DISC data and safety monitoring activities include:  
• Review of clinical trial conducted for progr ess and safety  
• Review of all adverse events requiring expedited reporting as defined in the protocol  
• Review of reports generated by data quality control review process  
• Notification of the sponsor -investigator of recommended action  
• Notification of sites coo rdinated by the UFHCC of adverse events requiring expedited 
reporting and subsequent committee recommendations for study modifications  
 
In compliance with the UFHCC data and safety monitoring plan, the PI will provide a Data Integrity 
and Safety Committee Report to DISC at the predetermined timelines for the level of risk category 
assigned during the initial SRMC review.  
 
 
UFHCC investigator -initiated protocols will be classified into one of the following categories of 
risk: 
• Level 1  – Low risk non -therapeut ic interventional trials.  
• Level 2 – Moderate risk therapeutic (i.e., drug, biologic, or device) trials using FDA 
approved or commercially available compounds or interventions.  
• Level 3  – High risk therapeutic trials (i.e., investigator -sponsored INDs, Phase  I trials, 
studies requiring biosafety approval, or other areas that may be designated by NIH as 
high risk).  
• Level 4  – Complex trials involving very high risk to subjects and a high level complexity 
(i.e., first in human or gene transfer studies).  
 
The PI will summarize and provide DISC with all pertinent data related to the level of risk assigned 
by SRMC.  
 
This protocol summary will include a minimum of the following:   
• The UF IRB assigned protocol number, UFHCC assigned protocol number, protocol ti tle, 
PI name, data coordinator name or primary study coordinator, regulatory coo rdinator 
name, and statistician  
• Date of initial UF IRB approval, date of most recent consent UF IRB approval/revision, 
date of UF IRB expiration, study  status, and phase of the  study, Study target accrual and 
study actual accrual.  
• Protocol objectives with supporting data and list of number of study participants who 
have met each objective.  
UF-STO-ETI-001  14 February 2022 
64 of 92  
       CONFIDENTIAL   Version 2. 2  • Measures of efficacy.  
• Early stopping rules with supporting data and a list of the number o f study participants 
who have met the early stopping rules.  
• Summary of toxicities and protocol deviations.  
• Summary of any recent literature which may affect the safety or ethics of the trial.  
 
13.2  Site Monitoring  
UFHCC monitors will make monitoring visits either remotely or to the trial sites periodically 
during the trial to ensure that  sites are complying with the protocol. Source documents will be 
reviewed for verification of agreement with data as submitted via the data collection system. The 
site investigator/institution guarantee access to source documents by UFHCC or its designee and 
appropriate regulatory agencies.  
 
The trial site may also be subject to quality assurance audit by any collaborating sponsors or  their 
designee as well as inspection by appropriate regulatory agencies.  
 
 
It is important for the site investigator and their relevant personnel to be available during the 
monitoring visits and possible audits and for sufficient time to be devoted to the  process.  
 
13.3  Principal Investigator Responsibilities  
As part of the responsibilities assumed by conducting this study, the Principal Investigator (PI) 
agrees to maintain and have available for monitoring adequate case records (accurate source 
documents and CRFs) for the subjects treated under this protocol.  
 
The PI will be primarily responsible for monitoring of adverse events, protocol violations, and 
other immediate protocol issues. The study coordinator will collect information on subjects 
enrolled th rough the use of electronic or paper adverse event (AE) forms, CRFs, and Informed 
Consent forms.  
 
14. EMERGENCY PROCEDURES  
 
14.1  Emergency Contact  
In emergency situations, the treating physician should contact the Principal Investigator by 
telephone at the  number listed on the title page of the protocol.  
 
14.2  Emergency Identification of Investigational Products  
UF-STO-ETI-001  14 February 2022 
65 of 92  
       CONFIDENTIAL   Version 2. 2  This is a non -blinded, open label, non -randomized study. Thus, there will be no need for 
unmasking procedures, and the identification of the invest igational product can be made by 
simple inquiry t o the investigational pharmacy.  
 
14.3  Emergency Treatment  
During and following a subject’s participation in the study, the treating physician and/or 
institution should ensure that adequate medical care is pr ovided to a subject for any adverse 
events, including clinically significant laboratory values, related to the study.  
 
15. ADMINISTRATIVE, ETHICAL, AND REGULATORY CONSIDERATIONS  
 
15.1  Good Clinical Practice  
 
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that the Principal Investigator and Co - 
Investigators abide by Good Clinical Practice (GCP), as described in International Conference on 
Harmonization (ICH) Guide line E6 and in accordance with the general ethical principles outlined 
in the Declaration of Helsinki.  
 
The study will be conducted in compliance with the protocol. The protocol, any amendments, 
and the subject informed consent will receive UF Institutiona l Review Board (IRB) approval before 
initiation of the study.  
 
The Principal Investigator will conduct all aspects of this study in accordance with applicable 
national, state, and local laws of the pertinent regulatory authorities.  
 
All potential serious b reaches must be reported immediately to the UFHCC DISC and UF IRB of 
record, if applicable. A serious breach is a breach of the conditions and principles of GCP in 
connection with the study or the protocol, which is likely to affect, to a significant degre e, the 
safety or physical or mental integrity of the subjects of the study or the scientific value of the 
study.  
 
15.2  Institutional Review Board  
Before study initiation, the investigator must have written and dated approval from the UF IRB 
for the protoco l, consent form, subject recruitment materials/process (e.g., advertisements), and 
any other written information to be provided to subjects. The investigator should also provide 
the UF IRB with a copy of the Investigator Brochure or product labeling, infor mation to be 
provided to subjects, and any updates. The investigator should provide the UF IRB with reports, 
updates, and other information (e.g., amendments, and administrative letters) according to 
UF-STO-ETI-001  14 February 2022 
66 of 92  
       CONFIDENTIAL   Version 2. 2  regulatory requirements or institution procedures.  
 
15.3  Compliance with Laws and Regulations  
It is intended that the proposed study be conducted according to the International Conference 
on Harmonization E6 Guideline for Good Clinical Practice (GCP) and the Declaration of Helsinki. 
Please refer to the Internat ional Conference on Harmonization and GCP:  
http://www.fda.gov/oc/gcp/guidance.html ; Declaration of Helsinki: 
http://www.fda.gov/oc/he alth/helsinki89.html ; Code of Federal Regulations, Title 21: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm  
 
All UF Health Cancer Center investi gator -initiated trials, meeting the criteria of the FDAAA’s 
applicable clinical trials, will be registered with ClinicalTrials.gov by the Protocol Development 
Officer or assigned designee. All studies must be registered no later than 21 days after enrollme nt 
of the first participant. The Protocol Development Officer will maintain the responsibility of 
updating trials registered with ClinicalTrials.gov; per the FDA’s updating requirements of 
information must be updated at least every twelve months and the re gistry must be updated 
within thirty days of any changes in recruitment status or completion of the study.  
15.4  Delegation of Investigator Responsibilities  
The Principal Investigator will ensure that all persons assisting with the study are adequately 
informed about the protocol, any amendments to the protocol, the study treatments, and their 
study -related duties and functions. The Principal Investigator will maintain a list of Co - 
Investigators and other appropriately qualified persons to whom he has deleg ated significant 
study -related duties.  
 
Study personnel involved in conducting this study will be qualified by education, training, and 
experience to perform their respective tasks. This study will not use the services of study 
personnel where sanctions have been invoked or where there has been scientific misconduct or 
fraud (e.g., loss of medical licensure; debarment). Systems with procedures that ensure the 
quality of every aspect of the study will be implemented.  
 
15.5  Subject Information and Informed Consent  
Before being enrolled in this clinical trial, the subject must consent to participate after the nature, 
scope, and possible consequences of the clinical study have been explained in a form 
understandable to him or her. An informed consent document that includes both information 
about the study and the consent form will be prepared and given to the subject. This document 
will contain all ICH, GCP, and locally required regulatory elements. The document must be in a 
language understandable to the subje ct and must specify the person who obtained informed 
consent.  
UF-STO-ETI-001  14 February 2022 
67 of 92  
       CONFIDENTIAL   Version 2. 2  After reading the informed consent document, the subject must give consent in writin g. The 
written informed consent will be obtained prior to conducting any study -related procedures or 
tests. Th e subject’s consent must be confirmed at the time of consent by the personally dated 
signature of the person conducting the informed consent discussions. A copy of the signed 
consent document must be given to the subject.  
The PI will retain the original si gned consent document. The PI will not undertake any measures 
specifically required only for the clinical study until valid consent has been obtained.  
 
15.6  Confidentiality  
All records identifying the subject will be kept confidential and, to the extent pe rmitted by the 
applicable laws and/or regulations, will not be made publicly available.  
 
Should direct access to medical records require a waiver or authorization separate from the 
subject’s statement of informed consent, it is the responsibility of the In vestigator to obtain such 
permission in writing from the appropriate individual.  
 
Subjects will be told that the UF IRB, UF Health DISC, or regulatory authorities may inspect their 
medical records to verify the information collected, and that all personal information made 
available for inspection will be handled in strictest confidence and in accordance with local data 
protection law.  
 
15.7  Protocol Amendments  
Once the study has started, amendments should be made only in exceptional cases. Protocol 
amendments cannot be implemented without prior written UF IRB approval except as necessary 
to eliminate immediate safety hazards to subjects. A protocol amendment intended to eliminate 
an apparent immediate hazard to subjects may be implemented immediately , provided the UF 
IRB and C RO are notified within five business days. All amendments will be submitted to the UF 
IRB and written verification that the amendment was submitted and subsequently approved is 
to be obtained.  
 
15.8  Case Report Forms  
The Principa l Investigator and/or his/her designee, will prepare and maintain adequate and 
accurate participant case histories with observations and data pertinent to the study. Study 
specific Case Report Forms (CRFs) will document safety and treatment outcomes for sa fety 
monitoring and data analysis. All study data will be entered into OnCore® via standardized CRFs 
in accordance with the CTMS study calendar, using single data entry with a secure access account.  
 
An electronic case report form (eCRF) is required and mu st be completed for each included 
UF-STO-ETI-001  14 February 2022 
68 of 92  
       CONFIDENTIAL   Version 2. 2  subject. The completed dataset is the sole property of UFHCC and should not be made available 
in any form to third parties, except for authorized representatives of appropriate 
Health/Regulatory Authorities, without  writte n permission from UFHCC.  
 
15.9  Record Retention  
Study documentation includes all eCRFs, data correction forms or queries, source documents, 
Sponsor -Investigator correspondence, monitoring logs/letters, and regulatory documents (e.g., 
protocol and amendment s, UF IRB correspondence and approval, signed subject  consent forms).  
 
Source documents include all recordings of observations or notations of clinical activities and all 
reports and records necessary for the evaluation and reconstruction of the clinical research 
study.  
 
Government agency regulations and directives require that all study documentation pertaining 
to the conduct of a clinical trial must be retained by the study investigator. In the case of a study 
with a drug seeking regulatory approval and marketing, these documents shall be retained for at 
least two years after the last approval of marketing application in an International Conference on 
Harmonization (ICH) region. In all other cases, study documents should be kept on file until three 
years after the completion and final study report of this investigational study.  
 
UF Health Cancer Center requires that all study documentation be maintained for at least 6 years 
from the date of final study publication. No study records may be destroyed without  prior 
authorization from UF.  
15.10 Sub -Site Management and Communication Plan  
 
On a weekly basis for the duration that the site has subjects on study treatment, the UFHCC 
Project Management Office will be in communication with each sub -site to receive upd ates on 
study and subject status.  Communication will be in the form of e -mail, phone, and weekly study 
meetings that include at least one representative from each site.  Adverse events and regulatory 
status approvals / updates will be standing agenda item s at these meetings.  Once all site subjects 
are completed with the treatment phase of the study (i.e., in the follow up phase, withdrawn, or 
deceased ), meeting frequency may be decreased.  
De-identified site data, as well as site study team records, will b e reviewed (at a minimum) 
approximately at least every  12-16 weeks to ensure accuracy and up -to-date certifications / local 
approvals are on file.  All local approval documentation by IRB or otherwise must be provided to 
UFHCC and contained in the site’s r egulatory files.   
Protocol amendments with red -lined, clean versions and a summary of changes will be provided 
to sites for IRB submission.  Consent form (ICF) amendments will be provided in the study’s model 
consent and will contain tracked changes.  Upd ates to the local ICF must be approved by UFHCC 
PMO prior to submission to the local IRB.  Other document updates such as to the Investigator 
Brochure and lab manual must be submitted to the local IRB as per their guidelines.   
UF-STO-ETI-001  14 February 2022 
69 of 92  
       CONFIDENTIAL   Version 2. 2  Activated secondary sites ar e expected to submit modifications to their local IRBs, per local 
guidelines within 4 weeks of receipt unless otherwise noted.  All approval documentation must 
be forwarded to UFHCC PMO within 2 weeks of approval.   If the IRB of record for a sub -site is 
UF-IRB-01, UFHCC PMO will submit updates on the site’s behalf with input from the sub -site(s).  
Approval will be provided via email to the sub -site(s) as soon as possible when obtained. The 
University of Florida IRB requires that all events meeting the defi nition of unanticipated problem 
or serious noncompliance be reported as outlined.  
Documentation of participating site’s IRB approval of annual continuing reviews, protocol 
amendments, SAE reports, and protocol deviations, regulatory violations and unantic ipated 
events must be kept on file at UFHCC PMO.    
UF-STO-ETI-001  14 February 2022 
70 of 92  
       CONFIDENTIAL   Version 2. 2  16. REFERENCES  
 
1. Wilkinson KD. Regulation of ubiquitin -dependent processes by deubiquitinating 
enzymes. FASEB J. Dec 1997;11(14):1245 -1256.  
2. Al-Hakim A, Escribano -Diaz C, Landry MC, et al. The ubiquitous role of ubiquitin in the 
DNA damage response. DNA Repair (Amst). Dec 2010;9(12):1229 -1240.  
3. de Napoles M, Mermoud JE, Wakao R, et al. Polycomb group proteins Ring1A/B link 
ubiquitylation of histone H2A to heritable gene silencing and X inactivation. Dev Cel l. 
Nov 2004;7(5):663 -676.  
4. Huang H, Kahana A, Gottschling DE, Prakash L, Liebman SW. The ubiquitin - conjugating 
enzyme Rad6 (Ubc2) is required for silencing in Saccharomyces cerevisiae. Mol Cell Biol. 
Nov 1997;17(11):6693 -6699.  
5. Turner SD, Ricci AR, Petropou los H, Genereaux J, Skerjanc IS, Brandl CJ. The E2 ubiquitin 
conjugase Rad6 is required for the ArgR/Mcm1 repression of ARG1 transcription. Mol 
Cell Biol. Jun 2002;22(12):4011 -4019.  
6. Doil C, Mailand N, Bekker -Jensen S, et al. RNF168 binds and amplifies ubiq uitin 
conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell. 
Feb 2009;136(3):435 -446.  
7. Lilley CE, Chaurushiya MS, Boutell C, et al. A viral E3 ligase targets RNF8 and RNF168 to 
control histone ubiquitination and DNA damage respons es. EMBO J. Mar 
2010;29(5):943 -955.  
8. Mattiroli F, Vissers JH, van Dijk WJ, et al. RNF168 ubiquitinates K13 -15 on H2A/H2AX to 
drive DNA damage signaling. C ell. Sep 2012;150(6):1182 -1195.  
9. Panier S, Durocher D. Regulatory ubiquitylation in response to DNA doub le-strand 
breaks. DNA Repair (Amst). Apr 2009;8(4):436 -443.  
10. Ginjala V, Nacerddine K, Kulkarni A, et al. BMI1 is recruited to DNA breaks and 
contributes to DNA damage -induced H2A ubiquitination and repair. Mol Cell Biol. May 
2011;31(10):1972 -1982.  
UF-STO-ETI-001  14 February 2022 
71 of 92  
       CONFIDENTIAL   Version 2. 2  11. Huen  MS, Grant R, Manke I, et al. RNF8 transduces the DNA -damage signal via histone 
ubiquitylation and checkpoint protein assembly. Cell. Nov 2007;131(5):901 - 914.  
12. Ismail IH, Davidson R, Gagné JP, Xu ZZ, Poirier GG, Hendzel MJ. Germline mutations in 
BAP1 impai r its function in DNA double -strand break repair. Cancer Res. Aug 
2014;74(16):4282 -4294.  
13. Kolas NK, Chapman JR, Nakada S, et al. Orchestration of the DNA -damage response by 
the RNF8 ubiquitin ligase. Science. Dec 2007;318(5856):1637 -1640.  
14. Mailand N, Bekker -Jensen S, Faustrup H, et al. RNF8 ubiquitylates histones at DNA 
double -strand breaks and promotes assembly of repair proteins. Cell. Nov 
2007;131(5):887 -900.  
15. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds 
to the BRCA 1 RING finger and enhances BRCA1 -mediated cell growth suppression. 
Oncogene. Mar 1998;16(9):1097 -1112.  
16. Ventii KH, Devi NS, Friedrich KL, et al. BRCA1 -associated protein -1 is a tumor suppressor 
that requires deubiquitinating activity and nuclear localizatio n. Cancer Res. Sep 
2008;68(17):6953 -6962.  
17. Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev 
Cancer. Mar 2013;13(3):153 -159.  
18. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p 
involved in the pathog enesis of lung and other cancers. Oncogene. Oct 
2002;21(45):6915 -6935.  
19. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. PARP inhibition: PARP1 and 
beyond. Nat Rev Cancer. Apr 2010;10(4):293 -301.  
20. Gradwohl G, Ménissier de Murcia JM, Molinete M, et al . The second zinc -finger domain 
of poly(ADP -ribose) polymerase determines specificity for single -stranded breaks in 
DNA. Proc Natl Acad Sci U S A. Apr 1990;87(8):2990 -2994.  
21. Shaheen M, Allen C, Nickoloff JA, Hromas R. Synthetic lethality: exploiting the add iction 
of cancer to DNA repair. Blood. Jun 2011;117(23):6074 -6082.  
UF-STO-ETI-001  14 February 2022 
72 of 92  
       CONFIDENTIAL   Version 2. 2  22. Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy.  
23. Nat Rev Cancer. Sep 2005;5(9):689 -698.  
24. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defec t in BRCA mutant 
cells as a therapeutic strategy. Nature. Apr 2005;434(7035):917 -921.  
25. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2 -deficient tumours with 
inhibitors of poly(ADP -ribose) polymerase. Nature. Apr 2005;434(7035):913 - 917.  
26. Bott M, Brevet M, Taylor BS, et al. The nuclear deubiquitinase BAP1 is commonly 
inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. 
Nat Genet. Jul 2011;43(7):668 -672.  
27. Murali R, Wiesner T, Scolyer RA. Tumours  associated with BAP1 mutations.  
28. Pathology. Feb 2013;45(2):116 -126.  
29. Brugarolas J. PBRM1 and BAP1 as novel targets for renal cell carcinoma. Cancer J.  
30. 2013 Jul -Aug 2013;19(4):324 -332.  
31. Andrici J, Goeppert B, Sioson L, et al. Loss of BAP1 Expression Occurs Fr equently in 
Intrahepatic Cholangiocarcinoma. Medicine (Baltimore). Jan 2016;95(2):e2491.  
32. Sulkowski PL, Corso CD, Robinson ND, et al. 2 -Hydroxyglutarate produced by 
neomorphic IDH mutations suppresses homologous recombination and induces PARP 
inhibitor sens itivity. Sci Transl Med. Feb 2017;9(375).  
33. Shen J, Peng Y, Wei L, et al. ARID1A Deficiency Impairs the DNA Damage Checkpoint and 
Sensitizes Cells to PARP Inhibitors. Cancer Discov. Jul 2015;5(7):752 -767.  
34. Shiloh Y, Ziv Y. The ATM protein kinase: regulating t he cellular response to genotoxic 
stress, and more. Nat Rev Mol Cell Biol. Apr 2013;14(4):197 -210.  
35. Stover EH, Konstantinopoulos PA, Matulonis UA, Swisher EM. Biomarkers of Response 
and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. Dec 
2016; 22(23):5651 -5660.  
36. Nam EA, Cortez D. ATR signalling: more than meeting at the fork. Biochem J. Jun 
2011;436(3):527 -536.  
37. Litman R, Peng M, Jin Z, et al. BACH1 is critical for homologous recombination and 
UF-STO-ETI-001  14 February 2022 
73 of 92  
       CONFIDENTIAL   Version 2. 2  appears to be the Fanconi anemia gene product FANCJ. C ancer Cell. Sep 2005;8(3):255 -
265.  
38. Li M, Yu X. Function of BRCA1 in the DNA damage response is mediated by ADP - 
ribosylation. Cancer Cell. May 2013;23(5):693 -704.  
39. Wu L, Davies SL, Levitt NC, Hickson ID. Potential role for the BLM helicase in 
recombinational repair via a conserved interaction with RAD51. J Biol Chem. Jun 
2001;276(22):19375 -19381.  
40. Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. Mar 
2014;134(5):1013 -1023.  
41. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double -
strand break repair. Mol Cell Biol. Jan 2004;24(2):708 -718.  
42. Esashi F, Christ N, Gannon J, et al. CDK-dependent phosphorylation of BRCA2 as a 
regulatory mechanism for recombinational repair. Nature. Mar 2005;434 (7033):598 -
604.  
43. Castillo A, Paul A, Sun B, et al. The BRCA1 -interacting protein Abraxas is required for 
genomic stability and tumor suppression. Cell Rep. Aug 2014;8(3):807 -817.  
44. Koppensteiner R, Samartzis EP, Noske A, et al. Effect of MRE11 loss on PARP - inhibitor 
sensitivity in endometrial cancer in vitro. PLoS One. 2014;9(6):e100041.  
45. Sharma S, Javadekar SM, Pandey M, Srivastava M, Kumari R, Raghavan SC. Homology 
and enzymatic requirements of microhomology -dependent alternative end joining. Cell 
Death Dis.  Mar 2015;6:e1697.  
46. Buisson R, Dion -Côté AM, Coulombe Y, et al. Cooperation of breast cancer proteins 
PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol 
Biol. Oct 2010;17(10):1247 -1254.  
47. Mateo J, Carreira S, Sandhu S, et al. DNA -Repair Defects and Olaparib in Metastatic 
Prostate Cancer. N Engl J Med. Oct 2015;373(18):1697 -1708.  
48. Tumini E, Barroso S, -Calero CP, Aguilera A. Roles of human POLD1 and POLD3 in 
genome stability. Sci Rep. Dec 2016;6:38873.  
UF-STO-ETI-001  14 February 2022 
74 of 92  
       CONFIDENTIAL   Version 2. 2  49. Lees -Miller SP, Meek K. Repair of DNA double strand breaks by non -homologous end 
joining. Biochimie. Nov 2003;85(11):1161 -1173.  
50. Goodwin JF, Knudsen KE. Beyond DNA repair: DNA -PK function in cancer. Cancer Discov. 
Oct 2014;4(10):1126 -1139.  
51. Riabinska A, Daheim M, Herter -Sprie GS, et al. Therapeutic targeting of a robust non - 
oncogene addiction to PRKDC in ATM -defective tumors. Sci Transl Med. Jun 
2013;5(189):189ra178.  
52. Ming M, He YY. PTEN in DNA damage repair. Cancer Lett. Jun 2012;319(2):125 -129.  
53. Mendes -Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN 
mutant cells with PARP inhibitors. EMBO Mol Med. Sep 2009;1(6 -7):315 -322.  
54. Chun J, Buechelmaier ES, Powell SN. Rad51 paralog complexes BCDX2 and CX3 act at 
different stages in the BRCA1 -BRCA2 -dependent homologous recom bination pathway. 
Mol Cell Biol. Jan 2013;33(2):387 -395.  
55. Prakash R, Zhang Y, Feng W, Jasin M. Homologous recombination and human health: the 
roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. Apr 
2015;7(4):a016600.  
56. Mazin AV, Ma zina OM, Bugreev DV, Rossi MJ. Rad54, the motor of homologous 
recombination. DNA Repair (Amst). Mar 2010;9(3):286 -302.  
57. Zou Y, Liu Y, Wu X, Shell SM. Functions of human replication protein A (RPA): from DNA 
replication to DNA damage and stress responses. J Cell Physiol. Aug 2006;208(2):267 -
273.  
58. Svendsen JM, Smogorzewska A, Sowa ME, et al. Mammalian BTBD12/SLX4 assembles a 
Holliday junction resolvase and is required for DNA repair. Cell. Jul 2009;138(1):63 -77. 
59. Saintigny Y, Makienko K, Swanson C, Emond MJ, Mon nat RJ. Homologous recombination 
resolution defect in werner syndrome. Mol Cell Biol. Oct 2002;22(20):6971 -6978.  
60. Kanagaraj R, Parasuraman P, Mihaljevic B, et al. Involvement of Werner syndrome 
protein in MUTYH -mediated repair of oxidative DNA damage. Nucle ic Acids Res. Sep 
2012;40(17):8449 -8459.  
UF-STO-ETI-001  14 February 2022 
75 of 92  
       CONFIDENTIAL   Version 2. 2  61. Thacker J, Zdzienicka MZ. The XRCC genes: expanding roles in DNA double -strand break 
repair. DNA Repair (Amst). 2004 Aug -Sep 2004;3(8 -9):1081 -1090.  
62. Michie C, Sandhu S, Schelman W. Final results of the phase I trial of niraparib (MK4827), 
a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept 
biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic 
ovarian, and castration resistant prostate cancer (CRPC). Paper presen ted at: ASCO2013.  
63. Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib Maintenance Therapy in Platinum - 
Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 12 2016;375(22):2154 -2164.  
UF-STO-ETI-001  14 February 2022 
76 of 90  
       CONFIDENTIAL   Version 2. 1  17. APPENDICES  
 
(Page intentionally left blank. Please proceed to the following page.)  
 
 
UF-STO-ETI-001    14 February 2022 
77 of 90  
CONFIDENTIAL   Version 2. 2  Appendix A : SCHEDULE OF EVENTS  
Visit:  SCREENING  BASELINE  ON-TREATMENT  EOT FOLLOW -UP 
Procedure:  (Day -21 to Day 0)  (Cycle 1/Day 
1/pre -dose)3 (Cycle 1 /Day  15 ± 
1 day)  (Cycle 2 & after/ 
Day 1)  (Within 7 days of last 
study drug 
administration)  (30 +/- 3 days  Post 
EOT)  
Informed Consent  X      
Medical History  X      
Toxicity Assessment  X X X X X X 
Physical Exam  X X X X X X 
Height  X X X X X X 
Weight  X X X X X X 
Vital Signs 11 X X X X X X 
ECOG PS  X X X X X X 
CMP  X X X X X X 
Pregnancy Test (Urine  or serum ) X X  X   
CBC w/Diff  X X4 X4 X X X 
Research Blood collection   X X X X X 
Diagnostic Imaging  Scan/TA1 X2   X6 X  
Tumor Biopsy  X7    X7  
Administration of Niraparib   X5 X5 X5   
Concomitant Medication Review  X X X X X X 
Adverse Event Review   X X 
 X X X10 
Survival assessment       X8 
Follow -up for MDS/AML       X 
 
 
UF-STO-ETI-001    14 February 2022 
78 of 90  
CONFIDENTIAL   Version 2. 2   
Bone marrow aspirate and biopsy and sample 
collection (whole blood) for cytogenetic 
analysis   X9 
Abbreviations:  PS=ECOG performance status; VS=vital signs (blood pressure, temperature, pulse and respiratory rates, weight and height); CBC /diff=complete blood count and white blood cell differential; CMP=12 
item complete metabol ic profile (sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, alkaline phosphatase, AST, AL T, total bilirubin, uric acid)  
1) TA= Tumor assessment by RECIST. Diagnostic CT scan, ultrasound, PET/CT scan and/or MRI  scan.  
2) The radiographic assessment must be repeated if there are more than 28 days between baseline and day  1. 
3) Baseline studies must be repeated on day 1 if there are more than 14 days between baseline and day  1. 
4) CBCs are to be collected weekly for Cycle 1. For Cycle  1, obtain CBC on Days 1, 8, 15, and  22. 
5) Niraparib to be taken daily during each  cycle.  
6) Imaging scan to be obtained  every  8 weeks (+/- 7 days) from first dose (Cycle 1 Day 1) until disease progression  or death  
7) FFPE from pre -existing tumor specimen  (from a routine biopsy) is  required to be submitted at study enrollment. See Section 9.3. Tumor biopsy upon disease progression is optional, but recomme nded.   Visit window 
for EOT visit does not apply for this procedure, as this may be done beyond 7 days past last study drug administration.  
8) Overall survival to be followed  
9) For any subject diagnosed with MDS/AML while on study, a bone marrow aspirate/biopsy must be completed by a local hematologist. A whole blood  sample will also be collected for cytogeneti c analysis (mutations 
of select myeloid -associated genes). Testing completed as part of standard of care is sufficient as long as the methods are acceptable to the S ponsor's Medical Monitor. The study site must receive a copy of the 
hematologist's report o f aspirate/biopsy findings (which must include a classification according to WHO criteria) and other sample testing results r elated to  MDS/AML.  
10) Collection of all SAEs and AESIs must continue for 90 days after the last administration of the investigational product (or to a minimum of 30 days post -treatment if the subject starts alternate anticancer  therapy).  
11) Blood pressure and heart rate should be monitored at least weekly for the first 2 months, and then monthly for the first year  and periodically thereafte r during treatment with niraparib. Participants may take 
readings at home or locally to them and a site visit is not necessarily required.   
 
 
 
 
 
 
 
UF-STO-ETI-001  14 Februar y 2022 
 
79 of 90  
       CONFIDENTIAL   Version 2. 2 
 Appendix B : ECOG PERFORMANCE STATUS SCALE  
ECOG Performance Status Scale  
Grade  Descriptions  
0 Normal activity  
Fully active, able to carry on all pre -disease performance without restriction  
1 Symptoms, but ambulatory  
Restricted in physically strenuous activity, but ambulatory and able to 
carry out work of a light or sedentary nature ( e.g., light housework, 
office work)  
2 In bed < 50% of the time  
Ambulatory and capable of all self -care, but unable to carry out any work 
activities  
Up and about more than 50% of waking hours  
 
3 In bed > 50% of the time  
Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours  
4 100% bedridden Completely disabled  
Cannot carry on any self -care  
Totally confined to bed or chair  
5 Dead  
UF-STO-ETI-001  14 February 2022 
 
80 of 92  
       CONFIDENTIAL   Version 2. 2  Appendix C : RECIST GUIDELINES (VERSION 1.1)  
Response and progression will be evaluated in this study using the international criteria 
proposed by the New Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST 
Guideline (version 1.1).  
 
Measurability of Tumor at Baseline  
 
Tumor lesions/lymph nodes will be categorized at baseline as measurable  or non -measurable. 
Measurable disease is defined by the presence of at least 1 measurable lesion.  
 
Measurable  
 
Tumor lesions: Measured in at least 1 dimension (longest diameter in the plane of 
measurement is to be recorded) with a minimum size of:  
• 10 mm b y computed tomography (CT) or magnetic resonance imaging (MRI) scan 
(slice thickness ≤5  mm)  
• 10 mm caliper measurement by clinical exam (non -measurable lesions if 
cannot be accurately measured with  calipers)  
• 20 mm by chest  X-ray. 
 
Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥15 mm in short axis when assessed by CT scan (CT scan thickness 
recommended to be ≤5 mm).  
 
Non -measurable  
 
All other lesions, including small lesions (longest diameter <10 mm or pa thological lymph 
nodes with ≥10 to <15 mm short axis) as well as truly non -measurable lesions. Lesions 
considered truly non -measurable include: leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmonis, inflammatory breast  disease, lymphangitis 
involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical 
exam that is not measureable by reproducible imaging techniques.  
 
Special Considerations for Lesion Measurability  
 
Bone Lesions : 
• Bone scan, P ET scan or plain films are not considered adequate imaging 
techniques to measure bone  lesions.  
• Lytic bone lesions or mixed lytic -blastic lesions, with identifiable soft t issue 
components, that can be evaluated by cross sectional imaging techniques such as  
CT or MRI, can be considered measurable lesions if the soft tissue component 
meets the definition of  measurability.  
UF-STO-ETI-001  14 February 2022 
 
81 of 92  
       CONFIDENTIAL   Version 2. 2  • Blastic bone lesions are  non-measurable.  
 
Cystic Lesions : 
• Simple cysts should not be considered as malignant lesions (neither measurable nor 
non- measurable)  
• Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability. If non -cystic lesions 
are presented in the same subjects , these are preferred for selection as  target  
lesions.  
 
Lesions with Prior Local Treatment : 
• Tumor lesions situated at a previously irradiated area, or in an area subjected to 
other loco -regional therapy, are non -measurable unless there has been 
demonstrated progression in the  lesion.  
 
Baseline  Documentation of Target and Non -Target Lesion  
 
Target Lesions  
 
When more than 1 measurable lesion is present at baseline, all lesions up to a maximum of 5 
lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be  identified as target lesions and will be recorded and measured at baseline. Non -
nodal target lesions should be selected on the basis of their size (lesions with the longest 
diameter), be representative of all involved organs, and can be reproduced in repe ated 
measurements.  
 
Measurable lymph nodes are target lesions if they meet the criteria of a short axis of ≥15 mm 
by CT scan. All measurements are to be recorded in the CRF in millimeters (or decimal 
fractions of centimeters [cm]).  
 
Non -target Lesions  
 
All other lesions (or sites of disease) are identified as non -target lesions (chosen based on the 
representativeness of involved organs and the ability to be reproduced in repeated 
measurements) and should be recorded at baseline. Measurement of these lesions  are not 
required but should be followed as ‘present,’ ‘absent,’ or in rare cases ‘unequivocal 
progression.’ In addition, it is possible to record multiple non -target lesions involving the same 
organ as a single item on the CRF (for example, multiple liver  metastases recorded as 1 liver 
lesion).  
 
Lymph nodes with short axis ≥10 mm but <15 mm should be considered non -target lesions. 
Nodes that have a short axis <10 mm are considered non -pathological and are not recorded 
or followed.  
UF-STO-ETI-001  14 February 2022 
 
82 of 92  
       CONFIDENTIAL   Version 2. 2  Specifications by Methods  of Measurement  
 
All measurements should be recorded in metric notation, using a ruler or calipers if clinically 
assessed. All baseline evaluations should be performed as closely as possible to the beginning 
of treatment and never more than 4 weeks before the beginning of the treatment.  
 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging -based evaluation 
should always be done rather than clinical e xamination unless the lesion(s) being followed 
cannot be imaged but  are assessed by clinical exam.  
 
An adequate volume of a suitable contrast agent should be given so that the metastases are 
demonstrated to best effect and a consistent method is used on subsequent examinations for 
any given subject . If prior to enrollment it is known a subject is not able to undergo CT scans 
with intravenous contrast due to allergy or renal insufficiency, the decision as to whether a 
non-contrast CT or MRI (with or without intravenous contrast) should be used to evaluate the 
subject at baseline and follow -up should be guided by the tumor type under investigation and 
the anatomic location of the disease.  
 
Clinical Lesions: Clinical lesions will be considered measurable only when they are superficial 
and ≥10 mm diameter as assessed using calipers (for example, skin nodule s). For the case of 
skin lesions, documentation by color photography, including a ruler to estimate the size of the 
lesion is recommended. When lesions can be evaluated by both clinical exam and imaging, 
imaging evaluation should be undertaken since it is more objective and may be reviewed at 
the end of the study.  
 
Chest X -ray: Chest CT is preferred over chest X -ray when progression is an important endpoint. 
Lesions on chest X -ray may be considered measurable if they are clearly defined and  
surrounded by ae rated  lung.  
 
CT and MRI : CT scan is the best currently available and reproducible method to measure lesions 
selected for response assessment. Measurability of lesions on CT scan is based on the 
assumption that CT slice thickness is ≤5 mm. When CT scan have  slice thickness >5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. MRI is also  
acceptable in certain situations (for example, for body scans). If there is concern about 
radiation exposure at CT, MRI may be used instead of  CT in selected  instances.  
 
Ultrasound: Ultrasound should not be used to measure lesion size. Ultrasound examinations 
cannot be reproduced in their entirety for independent review at a later date and, because 
they  are operator dependent, it cannot be guara nteed that the same technique and 
measurements will be taken from one assessment to the next. If new lesions are identified by 
ultrasound in the course of the study, confirmation by CT or MRI is  advised.  
 
UF-STO-ETI-001  14 February 2022 
 
83 of 92  
       CONFIDENTIAL   Version 2. 2  Endoscopy, Laparoscopy : The utilization of these te chniques for objective tumor evaluation is 
not advised. However, such techniques can be useful to confirm complete pathological 
response when biopsies are obtained or to determine relapse in trials where recurrence 
following complete response or surgical r esection is an endpoint.  
 
Tumor Markers : Tumor markers alone cannot be used to assess tumor response. If markers 
are initially above the upper normal limit, they must normalize for a subject to be considered 
in complete response (CR).  
 
Cytology, Histology : These techniques can be used to differentiate between partial  responses 
(PR) and complete response (CR) in rare cases if required by protocol (for example, residual 
lesions in tumor types such as germ cell tumors, where known residual benign tumors  can 
remain). When effusions are known to be a potential adverse effect of treatment (for example, 
with certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during tr eatment can be considered 
if\ the measurable tumor has met criteria for response or stable disease (SD) in order to 
differentiate between response (or SD) and progressive disease (PD).  
 
PET Scan (FDG -PET, PET CT) : PET is not recommended for lesion assessme nt. If a new lesion is 
found by PET, another assessment must be done by CT, unless the PET CT is of diagnostic 
quality. If CT is done to confirm the results of the earlier PET scan, the date of progression 
must be reported as the earlier date of the PET sc an. 
 
Bone Scan : If lesions measured by bone scan are reported at baseline, it is necessary to repeat 
the bone scan when trying to identify a complete response (CR) or partial response (PR) in 
target disease or when progression in bone is suspected.  
 
Respon se Criteria  
 
Evaluation of Target Lesions  
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non -target) must have reduction in short axis to <10 mm. Tumor marker 
results must have normalized.  
 
Part ial Response (PR): At least a 30% decrease in the sum of diameter of target lesions, taking 
as reference the baseline sum diameters.  
 
Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (including the baseline sum if that is the 
smallest). In addition to the relative increase of 20%, the sum must also demonstrate an 
absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered 
progres sion.  
UF-STO-ETI-001  14 February 2022 
 
84 of 92  
       CONFIDENTIAL   Version 2. 2  For equivocal findings of progression (for example, very small and uncertain new lesions; 
cystic changes or necrosis in existing lesions), treatment may continue until the next 
scheduled assessment. If at the next scheduled assessment, progression is  confirmed, the date 
of progression should be the earlier date when progression was suspected.  
 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diameters wh ile on study.  
 
Not Evaluable (NE): When an incomplete radiologic assessment of target lesions is performed 
or there is a change in the method of measurement from baseline that impacts the ability to 
make a reliable evaluation of response.  
 
Evaluation of Non -target Lesions  
Complete Response: Disappearance of all non -target lesions and normalization of tumor 
marker level. All lymph nodes must be non -pathological or normal in size (<10 mm short axis).  
 
Non-CR/ non -PD: Persistence of 1 or more non -target lesi ons and/or maintenance of 
tumor marker level above the normal limits.  
 
Progressive Disease: Unequivocal progression of existing non -target lesions. The appearance 
of 1 or more new lesions is also considered progression.  
 
Not Evaluable : When a change in method of measurement from baseline occurs and impacts 
the ability to make a reliable evaluation of response.  
 
Evaluation of Best Overall Response  
 
The best overall response is the best response recorded from the start of the study treatment 
until the earl iest of objective progression or start of new anticancer therapy, taking into 
account any requirement for confirmation. The subject’s best overall response assignment will 
depend on the findings of both target and non -target disease and will also take into  
consideration the appearance of new lesions. The best overall response will be calculated via 
an algorithm using the assessment responses provided by the investigator over the course of 
the trial.  
 
Time Point Response  
 
It is assumed that at each protocol -specified time point, a response assessment occurs. (When 
no imaging/measurement is done at all at a particular time point, the subject is not evaluable 
(NE) at that time point.) Table 8 provides a summary of the overall response status calculation 
at each  time point for subjects who have measurable disease at baseline.  
 
UF-STO-ETI-001  14 February 2022 
 
85 of 92  
       CONFIDENTIAL   Version 2. 2  Table 8- Time Point Response: Subjects with Target or Measurable  Disease  
 
Target Lesions  Non -target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non -CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non -PD or not all evaluated  No PR 
SD Non -PD or not all evaluated  No SD 
Not all Evaluated  Non -PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
Abbreviations: CR = complete response; NE = not evaluable; PD = progressive disease; PR 
= partial response; SD = stable disease  
 
Table 9 is to be used when subjects have non-measurable  disease only . 
 
Table 9- Time Point Response: Subjects with Non -Target or Non -Measurable  Disease  
Non -target Lesions  New Lesions  Overall Response  
CR No CR 
Non -CR/non -PD No Non -CR/non -PDa 
Not all evaluable  No NE 
Unequivocal  Yes or No  PD 
Any Yes PD 
Abbreviations: CR = complete response; NE = not evaluable; PD = progressive disease; SD = 
stable disease.  
a non-CR/non -PD is preferred over SD for non -target disease due to SD being 
increasingly used as an endpoint for assessment in trials; to assign this category when 
no lesions can be measured is not advised.  
 
 
UF-STO-ETI-001  14 February 2022 
 
86 of 92  
       CONFIDENTIAL   Version 2. 2  Frequency of Tumor Re -Evaluation  
 
A baseline tumor evaluation must be performed within 4 weeks before subject begins study 
treatment. Frequency of tumor re -evaluation while on and adapted to treatment should be 
protocol -specific and adapted to the type and schedule of treatment. Normally, all target and 
non- target sites are evaluated at each assessment using the same method. However, bone 
scans may need to be repeated only when CR is identified in target disease or when progression 
in bone is suspected.  
 
Duration of Response  
 
Duration of O verall Response  
The duration of overall response is measured from the time measurement criteria are first met 
for CR or PR (whichever is first recorded) until the first date that disease is recurrent or 
objective progression is observed (taking as referenc e for PD the smallest measurements 
recorded on study).  
 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented.  
 
Duration of Stable Disease  
Stable  disease is measured from the start of the treatment (in randomized trials, from date 
of randomization) until the criteria for objective progression are met, taking as reference the 
smallest sum on study (if the baseline sum is the smallest, that is the re ference for calculation 
of PD).  
  
UF-STO-ETI-001  14 February 2022 
 
87 of 92  
       CONFIDENTIAL   Version 2. 2  Appendix D : SUBJECT PILL DIARY  
Subject Pill Diary  
Treatment Date  Time  100 mg Niraparib pill  Comments  
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
22    
23    
24    
25    
26    
27    
28    
Subject’s  Name    Cycle  #    
Subject’s  Signature:     
 
Research Office will complete this section:  
1. Complete  dates:  Start  date    End Date    
2. Total number of Niraparib pills to be taken (per protocol)(100  mg):    
3. Compliance  rate  % 
4. Physician/Nurse/Research Staff’s  signature:    ________________ _______________________  
 
UF-STO-ETI-001  14 February 2022 
 
88 of 92  
       CONFIDENTIAL   Version 2. 2  18. SUMMARY OF CHANGES  
 
Version  Section(s)  
Affected  Change History  Date of 
Changes  
2.0 
 
 
 
 Throughout 
protocol  The word patient replaced with subject . 10-Oct-2019 
Site Protocol 
Signature Page  Signature lines added for local investigators  
Study Design  Updated  
This is a prospective, open -label phase II study in two 
biologically distinct cohorts . 
Inclusion 
Criteria  Removed Criteria  
Must be willing to provide blood/serum/plasma for all aspects 
of protocol specific research purposes.  
Updated Criteria  
Must have formalin -fixed paraffin embedded (FFPE) tissue 
available for research purposes. Tissue must have been obtained 
within the last 3 years from a core or excisional biopsy . 
A medical history with prior exposure to standard systemic 
therapy (having ex hausted or declined all known  and currently 
approved  effec tive life prolonging therapies.  
Section 1.6.1   Information regarding routine safety monitoring of PN001 has 
been removed.  
Section 2.0  Updated  
2.1 Primary  
To determine the objective response rate (ORR)  for subjects with 
BAP1 and other DDR repair pathway deficiencies treated with 
niraparib . 
2.2 Secondary  
To determine the median progression free survival (PFS) and 
estimate PFS at 3 and 6 months in each cohort and histologic 
subsets of subjects. PFS is defined as the duration of time from 
study entry to time of progression or death or the date of last 
contact, whichever occurs first.  
Section 4.1 Updated  
A total of 47 subjects are to be enrolled with thirty -five subjects 
in Cohort A and twelve subjects in Cohort B.  Additionally, there 
is the possibility of further subject enrollment (a pre -specified 
optional expansion cohort of up to an additional 20 subj ects [to 
obtain 18 evaluable]) based on meeting a minimum ORR in each 
specific histology identified in Cohort A (See Section 12.1).  
Section 5.0   Updated  
All consented  subjects must be entered into the University of 
Florida’s Clinical Trial Management System (OnCore) prior to 
assignment of a subject identification number.   This is not 
registration into the trial. The study team must submit the 
UF-STO-ETI-001  14 February 2022 
 
89 of 92  
       CONFIDENTIAL   Version 2. 2  Version  Section(s)  
Affected  Change History  Date of 
Changes  
completed study specific eligibility checklist, supporting source 
documentation and a copy of the signed inform ed consent 
document(s) to the UFHCC Project Management Office (PMO; 
PMO@cancer.ufl.edu) or their assigned Project Manager.  
Unsigned eligibility checklists or eligibility packets with missing 
or incomplete information may be  returned to the study team. 
Upo n receipt of a completed eligibility packet, the designated 
Project Manager will review the source to verify eligibility and 
assign a subject number.  If eligibility cannot be confirmed, the 
project manager will query the site for clarification or addition al 
documents as needed. Subjects failing to meet all study 
eligibility requirements will not be able to participate in the trial.  
Section 6.1   Updated  
CT or PET/CT scans, or MRI scans of the chest, abdomen, and 
pelvis will be obtained for tumor measurement (NOTE: baseline 
study imaging must be performed within 28 days prior to 
initiation of study therapy).  Imaging studies used at study entry 
to establis h baseline tumor measurement(s) should be the 
imaging modalities used to monit or subsequent disease 
response.  
Section 6.5  Updated  
A tumor biopsy will be done upon progression of disease (with 
subject’s permission) for research purposes. The timing of t he 
research biopsy should be ideally within 7 days of the EOT visit 
or at least prior to the start of any subsequent anticancer 
therapy.  
Added  
If feasible, the EOT visit, except for the biopsy noted in 6.5, 
should be performed within seven days regardless  of the 
reason for discontinuation.  If the subject withdraws consent, 
however, no further study procedures can proceed.”  
Section 6.6   +/- 3 days window has been added  
Added  
Follow -up Evaluations should occur regardless of the reason for 
discontinuati on.  If the subject withdraws consent, however, 
no further study procedures can proceed  
Updated  
Subjects will additionally be followed every three months for 
vital statistics and development of MDS/AML until death.  
Section 7.1  Updated  
*For subjects  whose starting dose is 2 capsules once daily, 
escalation to 3 capsules once daily is  required at the discretion 
of the treating provider at the beginning of cycle 3 , if no 
treatment interruption or discontinuation was required during 
the first 2 cycles of  therapy, and the treating physician 
UF-STO-ETI-001  14 February 2022 
 
90 of 92  
       CONFIDENTIAL   Version 2. 2  Version  Section(s)  
Affected  Change History  Date of 
Changes  
documents no other justification to maintain the lower dose.”  
Table 3  Niraparib d osing has been updated  
Section 7.3  Added  
If initial starting dose was 200 mg/day but subsequently 
increased to 300 mg/day at cycle 2, dose reductions are to 
follow as if they started at 300 mg/day.”  
Section 7.3.1  Updated  
Withhold niraparib for a maximum of 28 days or until adverse 
reaction has improved to < Grade 1. Resume niraparib at a one 
dose level reduction per Table 4.”  
Section 7.3.2  Added  
*** Discontinue niraparib if the platelet count, neutrophils 
and/or hemoglobin have not returned to acceptable levels 
within 28 days of the dose interruption period, or if the subject 
has already undergone dose red uction to 100 mg once 
daily.***  
Section 8.3   Updated  
Subjects who do not receive any doses of study drug will be 
replaced. Subjects who receive any dose of study drug will 
contribute to safety and toxicity data, but  will be replaced if 
they cannot provide response assessmen t due to study 
discontinuation for reasons other than disease progression or 
toxicity.”  
Section 9.1  Added  
Discussion with the PI prior to biopsy is recommended.  
Section 11.1.1  Updated  
Results in death,  unless the death is due to expected disease 
progression as outlined in section 11.2.  
Section 11.4.4  Fax number has been changed to +1 -866-750-6823  
Section 12.1  Updated  
A sample size of 9 patients achieves at least  90% power to 
detect a difference of 40%”  
Section 12.2  Removed  
Subjects who do not have a tumor response assessment for any 
reason will be considered nonresponders and will be included 
in the denominator when calculating the response rate.  
Section 12.3  Added  
The PFS is defined as the duration of time from study entry to 
time of progression or death or the date of last contact, 
whichever occurs first. OS is defined as the time from study 
entry to time of death or date of last contact.  
Updated  
Subjects who did not progress ( death ) or are lost to follow -up 
UF-STO-ETI-001  14 February 2022 
 
91 of 92  
       CONFIDENTIAL   Version 2. 2  Version  Section(s)  
Affected  Change History  Date of 
Changes  
will be c ensored at the day of their last objective tumor 
assessment.  
Section 13.2  Updated  
UFHCC monitors will make monitoring visits either remotely or 
to the trial sites periodically during the trial to ensure that sites 
are complying with the protocol.  
Appendix A  Updated  
6) Imaging scan to be obtained every 8 weeks until progression.  
 
7) FFPE from pre -existing tumor specimen (from a routine 
biopsy) is required to be submitted at study enrollment. See 
Section 9.3. Tumor biopsy upon disease progression is optional, 
but recommended.  Visit window for EOT visit does not apply for 
this proce dure, as this may be done beyond 7 days past last 
study drug administration.  
 
Removed   
8) Overall survival to be followed for 5 years following the last 
dose of niraparib.  
2.1  Abbreviations  Added GSK  29-Oct-2020  
Throughout 
protocol  
 -Added “urine or serum” for pregnancy test  
-Updated TESARO to TESARO/GSK  
-Added +/- 1 day to dosing cycle to be consistent with visit 
windows  
-Updated at least 8 weeks to approximately 8 weeks for study 
participants on the study.  
Inclusion 
Criteria  in 
Protocol 
Synopsis  and 
Section 4.2  Added “oral” in front of corticosteroids  
Exclusion 
Criteria  in 
Protocol 
Synopsis and 
Section 4.2  Corrected Exclusion Criteria lettering  
Section 6.4, 
Appendix A 
#6 Imaging intervals clarified to be every 8 weeks +/ - 7 days from 
C1D1  
Section 7.3 
(Table 4)  If starting dose is 2 capsules once daily, then escalation to 3 
capsules once daily, at the beginning of cycle 3  
Section 10.6   Added hypertension and PRES language from IB v11.  
Section 11.4. 3 Updated email address and name to current GSK for reportable 
events  
UF-STO-ETI-001  14 February 2022 
 
92 of 92  
       CONFIDENTIAL   Version 2. 2  Version  Section(s)  
Affected  Change History  Date of 
Changes  
 
 Section 15.10  Added Subsite Management and Communication Plan   
Appendix A 
#11 Added footnote #11 about heart rate and blood pressure 
monitoring.  
 
2.2 Title Page  Added Dr.Franke as Junior PI  14-Feb-2022  
 